



(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 33/00 (2006.01)

A61K 31/00 (2006.01) C07K 16/32 (2006.01)

(21) International Application Number:

PCT/US2012/029292

(22) International Filing Date:

15 March 2012 (15.03.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/452,976 15 March 2011 (15.03.2011) US

61/452,974 15 March 2011 (15.03.2011) US

(71) Applicant (for all designated States except US): MER-

RIMACK PHARMACEUTICALS, INC. [US/US]; One Kendall Square, Suite B7201, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GARCIA, Gabriela

[BR/US]; 14 Knoll St., Roslindale, MA 02131 (US). KU-

BASEK, William [US/US]; 165 Fairview Ave., Belmont,

MA 02478 (US). LAHDENRANTA, Maria, Johanna

[FI/US]; 29 Wendell St., #2, Cambridge, MA 02138 (US).

MACBEATH, Gavin [US/US]; 4222 Kirkbride Drive,

Danvers, MA 01923 (US). MCDONAGH, Charlotte

[GB/US]; 11 Sargent Road, Winchester, MA 01890 (US).

MOYO, Victor [ZW/US]; 1694 Main Street, Apt. #5,

Concord, MA 01742 (US). ONSUM, Matthew, David

[US/US]; 90 Bynner Street, Jamaica Plain, MA 02130

(US). SEVECKA, Mark [DE/US]; 333 Pearl St., Cam-

bridge, MA 02139 (US). WAINSELBAUM, Marisa

[AR/US]; 1 Emerson Pl, Apt. 12h, Boston, MA 02114 (US). ZHANG, Bo [CN/US]; 14 Village Row, Lynnfield, MA 01940 (US).

(74) Agents: REMILLARD, Jane, E. et al.; Nelson Mullins

Riley & Scarborough Llp, One Post Office Square, Boston, MA 02109-2127 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: OVERCOMING RESISTANCE TO ERBB PATHWAY INHIBITORS

(57) Abstract: Provided are methods for overcoming resistance to an ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor. The resistance may be acquired resistance to an EGFR inhibitor, such as acquired resistance to gefitinib. In the methods provided, a subject exhibiting resistance to an ErbB pathway inhibitor is selected and both an ErbB 3 inhibitor and a second ErbB pathway inhibitor are administered to the subject, such as an EGFR inhibitor or a HER2 inhibitor. Also provided are methods for inhibiting the growth of a tumor comprising a T790M EGFR mutation by contacting the tumor with an ErbB3 inhibitor and an EGFR inhibitor. Compositions for overcoming resistance to an ErbB pathway inhibitor, comprising both an ErbB 3 inhibitor and a second ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor, are also provided.



WO 2012/125864 A2

OVERCOMING RESISTANCE TO ERBB PATHWAY INHIBITORS

Background

The ERBB family of receptor tyrosine kinases include EGFR (HER1), HER2 (ErbB2), ERBB3 (HER3), and ERBB4 (HER4). Over the past ten years, it has become evident that many epithelial cancers require EGFR or HER2 signaling for their growth and survival. Agents targeting EGFR have become widely used for the treatment of cancer such as lung cancer, colorectal cancer, head and neck cancer and, typically in combination with gemcitabine, pancreatic cancer. For example, small molecule tyrosine kinase inhibitors (TKIs) that downregulate the EGFR signaling pathway have been developed, such as gefitinib (Iressa®), which is indicated for the treatment of non-small cell lung cancer, erlotinib (Tarceva®), which is indicated for the treatment of non-small cell lung cancer and pancreatic cancer, and lapatinib (Tykerb®), which is indicated for the treatment of HER2-positive breast cancer. Furthermore, antibodies specific for EGFR have been developed, such as the humanized monoclonal antibody cetuximab (Erbix®), which is indicated for the treatment of colorectal cancer and head and neck cancer. Agents targeting HER2 also have become widely used for the treatment of cancer such as breast cancer. An example of an agent targeting HER2 is the humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin®), which is used around the world for the treatment of HER2 overexpressing breast cancer.

Recent studies have found that cancers that are sensitive to EGFR inhibitors are unique in that phosphoinositide 3-kinase (PI3K) signaling is under the sole control of EGFR. For the EGFR inhibitors to be effective, they must cause downregulation of the PI3K/AKT pathway (Bianco, R. *et al.* (2003) *Oncogene* 22:2812-2822). While patients with EGFR-driven cancers often initially respond well to EGFR-targeted therapies, over time many patients that were initially responsive suffer from recurrence and develop tumors refractory to the original treatment. Furthermore, certain EGFR-positive cancers exhibit a predisposition to resistance to EGFR-targeted therapies. One way in which such resistance has been observed to develop is through mutation of EGFR. The “T790M EGFR mutation” comprises and is identified by a change of a threonine, which is present at position 790 of wild-type EGFR, to a methionine. This mutation, which locates to the kinase domain of EGFR, has been described, *e.g.*, by Kobayashi, S. *et al.* (2005) *N. Engl. J. Med.* 352:786-792; and Pao, W. *et al.* (2005) *PLoS Med.* 2:225-235.

Persistent activation of the PI3K signaling pathway through ErbB3 also has been associated with gefitinib resistance (Engelman *et al.* (2005), *supra*; Engelman *et al.* (2007) *supra*).

Resistance to HER2 inhibitors, such as trastuzumab and lapatinib, also has been reported. Similar to EGFR inhibitor resistance, persistent activation of the PI3K/AKT signaling

pathway is at least one of the mechanisms reported for the acquired resistance to HER2 inhibitors.

Studies have identified ErbB3, which is a kinase-dead member of the ErbB family, as an activator of PI3K/AKT signaling in EGFR dependent cancers (Engelman, J.A. *et al.* (2005) *Proc. Natl. Acad. Sci. USA* 102:3788-3793; Engelman, J.A. *et al.* (2007) *Science* 316:1039-1045; In these cells, ErbB3 is tyrosine phosphorylated in an EGFR-dependent manner and then directly binds PI3K. Upon inhibition of EGFR, ErbB3 phosphorylation is lost, it no longer binds PI3K and there is loss of PI3K/AKT signaling (Engelman, J.A. *et al.* (2005) *Proc. Natl. Acad. Sci. USA* 102:3788-3793; Engelman, J.A. *et al.* (2007) *Science* 316:1039-1045). Furthermore, downregulation of ErbB3 using short hairpin RNA (shRNA) leads to a decrease in AKT phosphorylation in EGFR dependent cancers (Engelman, J.A. *et al.* (2005) *Proc. Natl. Acad. Sci. USA* 102:3788-3793). Similarly, ErbB3 is a major activator of PI3K in HER2 amplified breast cancers. Trastuzumab treatment leads to loss of ErbB3 phosphorylation, dissociation between ErbB3 and PI3K and loss of AKT phosphorylation in these cancers. Thus, signaling through ErbB3 is thought to be a major mechanism of PI3K/AKT activation in both EGFR and HER2 driven cancers.

There are also examples of resistance that implicate EGFR, HER2 and MET in reactivating ErbB3 (Engelman, J.A. *et al.* (2006) *J. Clin. Invest.* 116:2695-2706; Engelman, J.A. *et al.* (2007) *Science* 316:1039-1045; Ritter, C.A. *et al.* (2007) *Clin. Cancer Res.* 13:4909-4919; Sergina, N.V. *et al.* (2007) *Nature* 445:437-441). In addition, heregulin-induced activation of HER2-ErbB3 heterodimers has also been associated with resistance to EGFR inhibitors (Zhou, B.B. *et al.* (2006) *Cancer Cell* 10:39-50).

In view of the foregoing, compositions and methods for overcoming resistance to ErbB pathway inhibitors, including EGFR inhibitors (such as TKIs and anti-EGFR antibodies) and HER2 inhibitors (such as TKIs and anti-HER2 antibodies), are being actively sought, as they promise to extend or restore the effectiveness of targeted cancer therapies.

Summary

Methods are provided for overcoming resistance to ErbB pathway inhibitors, as well as pharmaceutical compositions that can be used in the practice of such methods. The methods and compositions provided herein are based, at least in part, on the discovery by the inventors that use of an ErbB3 inhibitor in combination with an ErbB pathway inhibitor can overcome tumor resistance to an ErbB pathway inhibitor. For example, use of a bispecific anti-ErbB3, anti-ErbB2 antibody (or an anti-ErbB3 antibody) in combination with an anti-EGFR antibody has been demonstrated to overcome acquired resistance *in vivo* to the small molecule EGFR inhibitor gefitinib.

Accordingly, in one aspect, a method for overcoming or preventing resistance of a tumor to an ErbB pathway inhibitor in a subject is provided, the method comprising:

selecting a subject with a tumor exhibiting, or at risk for developing, resistance to an ErbB pathway inhibitor; and

administering to the subject (i) an ErbB3 inhibitor and (ii) an ErbB pathway inhibitor.

The ErbB pathway inhibitor administered to the subject does not need to be the same ErbB pathway inhibitor to which the subject is resistant, although typically, the ErbB pathway inhibitor administered to the subject will be directed against the same ErbB pathway as the ErbB pathway inhibitor to which the subject is resistant. For example, a subject who exhibits resistance to the EGFR pathway inhibitor gefitinib may be co-administered an ErbB3 inhibitor and an EGFR inhibitor, which EGFR inhibitor can be, for example, gefitinib or the anti-EGFR antibody cetuximab.

In certain embodiments, the resistance exhibited by the subject to the ErbB pathway inhibitor is acquired resistance. In one embodiment, the acquired resistance is acquired resistance to an EGFR inhibitor, such as acquired resistance wherein the EGFR in the tumor comprises tumor cells comprising an EGFR gene comprising a T790M EGFR mutation. In another embodiment the tumor comprises tumor cells comprising a KRAS gene comprising at least one KRAS mutation, e.g., a G12S, G12C, or G12V KRAS mutation or a Q61R KRAS mutation. In one embodiment, the acquired resistance is resistance to gefitinib. In another embodiment, the acquired resistance is acquired resistance to a HER2 inhibitor, such as acquired resistance to trastuzumab. In various embodiments, the resistance exhibited by the subject is associated with reactivation of PI3K/AKT signaling in tumor cells in the subject.

In one embodiment, the ErbB3 inhibitor administered to the subject is an anti-ErbB3 antibody. An exemplary anti-ErbB3 antibody is MM-121 (Ab #6), comprising V_H and V_L sequences as shown in SEQ ID NOS: 1 and 2, respectively. Alternately, the anti-ErbB3 antibody is an antibody that comprises the heavy and light chain CDRs of MM-121 (*i.e.*, the anti-ErbB3 antibody comprises an antibody comprising V_H CDR1, 2 and 3 sequences as shown in SEQ ID NOS: 3-5, respectively, and V_L CDR1, 2 and 3 sequences as shown in SEQ ID NOS: 6-8, respectively). In another embodiment, the anti-ErbB3 antibody is an antibody having heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOS 42 and 43, respectively. In other embodiments, the anti-ErbB3 antibody is Ab #3 (comprising V_H and V_L sequences as shown in SEQ ID NOS: 9 and 10, respectively), Ab #14 (comprising V_H and V_L sequences as shown in SEQ ID NOS: 17 and 18, respectively), Ab #17 (comprising V_H and V_L sequences as shown in SEQ ID NOS: 25 and 26, respectively) or Ab #19 (comprising V_H and V_L sequences as shown in SEQ ID NOS: 33 and 34, respectively). In still other embodiments, the anti-ErbB3 antibody is selected from mAb 1B4C3 or mAb 2D1D12 or humanized versions thereof, mAb 205.10 (e.g., mAb 205.10.1, mAb 205.10.2, or mAb 205.10.3) (Roche-Glycart), AMG-888 (U3-1287 -- U3 Pharma AG and Amgen), AV-203 (Aveo Pharmaceuticals) and humanized mAb 8B8. Typically, the ErbB3 inhibitor inhibits PI3K/AKT signaling.

In one embodiment, the ErbB3 inhibitor administered to the subject is a bispecific anti-

ErbB3, anti-ErbB2 antibody such as MM-111, which comprises two scFvs in a Human Serum Albumin (HSA) conjugate as set forth in SEQ ID NO:44. MM-111 abrogates heregulin binding to ErbB2/ErbB3 and inhibits heregulin activation of ErbB2/ErbB3 without significantly affecting ErbB2 biological activity. A number of bispecific anti-ErbB2/antiErbB3 antibodies that are scFv HSA conjugates, including MM-111 (also referred to as B2B3-1), as well as A5-HSA-ML3.9, A5-HSA-B1D2, B12-HSA-B1D2, A5-HSA-F5B6H2, H3-HSA-F5B6H2, and F4-HSA-F5B6H2, are described in co-pending U.S. patent application Publication No. 20110059076, and PCT publication number WO2009/126920. Other suitable bispecific anti-ErbB2/antiErbB3 antibodies are disclosed and claimed in US Patent Nos. 7,332,580 and 7,332,585. MM-111 is currently undergoing clinical trials, including an open-label Phase 1-2 and pharmacologic study of MM-111 in patients with advanced, refractory HER2 positive cancers, and an open-label Phase 1-2 trial of MM-111 in combination with trastuzumab (Herceptin[®]) in patients with advanced HER2 positive breast cancer. In certain embodiments, the ErbB3 inhibitor inhibits PI3K/AKT signaling.

In one embodiment, the ErbB pathway inhibitor administered to the subject is an EGFR inhibitor. For example, the EGFR inhibitor can be an anti-EGFR antibody such as cetuximab. Other exemplary anti-EGFR antibodies are MM-151, Sym004, matuzumab, panitumumab, nimotuzumab and mAb 806.

In another embodiment, the EGFR inhibitor administered to the subject is a small molecule inhibitor of EGFR signaling such as gefitinib. Other exemplary small molecule inhibitors of EGFR signaling are afatinib, lapatinib, canertinib, erlotinib HCL, pelitinib, PKI-166, PD158780, and AG 1478.

In another embodiment, the ErbB pathway inhibitor administered to the subject is a HER2 inhibitor. For example, the HER2 inhibitor can be an anti-HER2 antibody such as trastuzumab. Alternatively, the HER2 inhibitor administered to the subject can be a small molecule inhibitor of HER2 signaling such as lapatinib.

In another aspect, a method of inhibiting growth of a tumor comprising cells comprising a T790M EGFR mutation cells is disclosed, the method comprising contacting the tumor with (i) an EGFR inhibitor; and (ii) an ErbB3 inhibitor. In a one embodiment, the ErbB3 inhibitor comprises an anti-ErbB3 antibody, such as one or more of the anti-ErbB3 antibodies set forth above. In another embodiment, the ErbB3 inhibitor comprises a bispecific anti-ErbB3, anti-ErbB2 antibody, such as one or more of the bispecific antibodies set forth above. In one embodiment, the ErbB3 inhibitor inhibits PI3K/AKT signaling. In another embodiment, the EGFR inhibitor comprises an anti-EGFR antibody, such as one or more of the antibodies set forth above. In yet another embodiment, the EGFR inhibitor comprises a small molecule inhibitor of EGFR signaling, such as one or more of the small molecule inhibitors set forth above.

In yet another aspect, a method of treating a tumor in a subject is provided, the method

comprising

selecting a subject with a tumor that, by biopsy tests positive for a T790M EGFR mutation, and

administering to the subject (i) an EGFR inhibitor; and (ii) an ErbB3 inhibitor.

In certain embodiments, the ErbB3 inhibitor administered to the subject comprises an anti-ErbB3 antibody, such as one or more of the anti-ErbB3 antibodies set forth above. In certain embodiments, the ErbB3 inhibitor administered to the subject comprises a bispecific anti-ErbB3, anti-ErbB2 antibody, such as one or more of the bispecific antibodies set forth above.

Exemplary ErbB3 inhibitors inhibit PI3K/AKT signaling. In another embodiment, the EGFR inhibitor administered to the subject comprises an anti-EGFR antibody, such as one or more of the antibodies set forth above. In yet another embodiment, the EGFR inhibitor administered to the subject comprises a small molecule inhibitor of EGFR signaling, such as one or more of the small molecule inhibitors set forth above.

The compositions and methods provided herein can be used to inhibit growth, invasiveness or metastasis of a tumor, or treat a subject carrying a tumor that is resistant to ErbB pathway inhibition. In one embodiment, the tumor is a lung cancer tumor, such as a non-small cell lung cancer (NSCLC) tumor, e.g., an adenocarcinoma NSCLC, a squamous cell carcinoma NSCLC, or a large cell carcinoma NSCLC. In other embodiments, the tumor can be a colorectal cancer, head and neck cancer, pancreatic cancer or breast cancer tumor.

In another aspect, pharmaceutical compositions for overcoming resistance to an ErbB pathway inhibitor are provided. The pharmaceutical compositions comprise one or more of an ErbB3 inhibitor as described above and an ErbB pathway inhibitor as described above. In one embodiment, the ErbB3 inhibitor and the ErbB pathway inhibitor are formulated with a pharmaceutical carrier into a single composition. In another embodiment, the ErbB3 inhibitor is formulated with a first pharmaceutical carrier to form a first composition, the ErbB pathway inhibitor is formulated with a second pharmaceutical carrier to form a second composition and the first and second composition are optionally packaged together.

Brief Description of the Drawings

Figure 1 is a series of graphs of ELISA assay results, showing inhibition of heregulin-induced phosphorylation of ErbB3 (pErbB3), AKT (pAKT) and ERK (pERK) in the ACHN, DU145 and OvCAR8 cell lines by the anti-ErbB3 antibody MM-121. Data represent the mean $\pm$ SD of two separate experiments.

Figure 2 is a series of graphs showing spheroid assays using EGFR wild-type NSCLC cell lines. Spheroid cell cultures were treated with EGF (10 nM), heregulin1- β 1 (HRG) (10 nM), both EGF and HRG (10 nM), or no exogenous ligands, as well as with erlotinib (1 μ M), MM-121 (1 μ M), a combination of the two (1 μ M each), or in the absence of drugs. Cell lines tested include adenocarcinoma cell lines NCI-H322M, Figure 2A; EKVX, Figure 2B; A549, Figure 2C; H358, Figure 2D, and squamous cell line SW-900, Figure 2E. The y-axes represent

relative live cell density.

Figure 3 is a series of graphs showing spheroid assays using EGFR wild-type NSCLC cell lines. Spheroid cell cultures were treated with doses of erlotinib ranging from 0 to 10 μ M, in either the absence or presence of heregulin-1 β 1(HRG), and in either the absence or presence of MM 121. Cells tested include the adenocarcinoma cell lines NCI-H322M (Figure 3A); EKVX (Figure 3B); A549 (Figure 3C); NCI-H358 (Figure 3D); NCI-H441 (Figure 3E), NCI-H2347 (Figure 3F); the squamous cell carcinoma cell line NCI-H2170 (Figure 3G), and the large cell carcinoma cell line NCI-H661 (Figure 3H). The y-axes represent relative live cell density.

Figure 4 is a graph showing cell viability of cisplatin sensitive (A2780) and resistant (A2780cis) cells after treatment with cisplatin. Cell viability (Y-axis) is given as % viability of media control and is plotted against drug concentration in log μ M.

Figure 5 shows images of three western blots probed with anti-pAKT. Shown are pAKT levels in lysate from A2780 cells treated with cisplatin (Figure 5A), A2780cis cells treated with cisplatin (Figure 5B), and A2780cis cells treated with MM-121 (Figure 5C). S indicates untreated sensitive cell control and R indicates untreated resistant cell control. The X-axes indicate the time the lysates were harvested in hours post drug treatment and the Y-axes indicate drug concentration in μ M.

Figure 6 comprises a series of graphs showing cell viability (as % control) of BT474-M3 cells *in vitro* (Y-axis) after treatment with: Figure 6A, lapatinib, Figure 6B trastuzumab, or Figure 6C, MM-111. For each the X-axis indicates drug concentration in nM.

Figure 7 comprises two graphs showing inhibition of AKT activation in heregulin-stimulated BT474-M3 cells (Y-axes, normalized amounts of pAKT) after treatment with: Figure 7A lapatinib, Figure 7B, trastuzumab. For each the X-axis shows ErbB pathway inhibitor concentrations as indicated. For each indicated lapatinib concentration along the X-axis in Figure 7A the grouped bars, reading from left to right, correspond to MM-111 concentrations of 0nM, 1nM, 4nM, 16nM, 63nM, 250nM, and 1000nM. For indicated trastuzumab concentration along the X-axis in Figure 7B the grouped bars, reading from left to right, correspond to trastuzumab concentrations of 0nM, 1nM, 10nM, 100nM, and 1000nM. The lines marked "basal" indicate the pAKT level in cells that were not stimulated with heregulin and were not treated with MM-111, lapatinib, or trastuzumab.

Figure 8 comprises two graphs showing reductions in tumor volumes in a BT474-M3 xenograft breast cancer xenograft model after treatment with: Figure 8A, MM-111, lapatinib, or a combination of MM-111 and lapatinib; Figure 8B MM-111, trastuzumab, or a combination of MM-111 and trastuzumab. The Y-axes represent mean tumor volume in mm³ and the x-axes represent time in days post tumor implant.

Figure 9 comprises three plots showing FACS analysis of ErbB receptors in trastuzumab-resistant BT474-M3 cells. For each, cell count (Y-axis) is plotted against fluorochrome emission intensity (X-axis) for: Figure 9A, ErbB2 receptor status – thick solid

black line = trastuzumab-resistant cells stained for ErbB2, thinner solid gray line = trastuzumab-resistant cells, unstained, dotted line = non-resistant cells, stained for ErbB2, dashed line = non-resistant cells, unstained; Figure 9B, EGFR status – thick solid black line = trastuzumab-resistant cells stained for EGFR, thinner solid gray line = trastuzumab-resistant cells, unstained, dotted line = non-resistant cells, stained for EGFR, dashed line = non-resistant cells, unstained; Figure 9C, ErbB3 status ErbB3 receptor status, thick solid black line = trastuzumab-resistant cells stained for ErbB3, thinner solid gray line = trastuzumab-resistant cells, unstained, dotted line = non-resistant cells, stained for ErbB3, dashed line = non-resistant cells, unstained.

Figure 10 comprises two graphs comparing the ability of: Figure 10A, trastuzumab and Figure 10B, MM-111, to inhibit cell growth in trastuzumab-resistant BT474-M3 cells. For each, the growth of parental (non-resistant) and trastuzumab-resistant BT474-M3 cells is shown as % of control (no trastuzumab or MM-111 added) cells (Y-axis) after treatment with a dose range of trastuzumab (A) or MM-111 (B) (X-axes, in nM trastuzumab or MM-111).

Figure 11 comprises two graphs comparing the ability of: Figure 11A, trastuzumab, and Figure 11B, MM-111, to inhibit cell growth in trastuzumab-resistant BT474-M3 cell spheroids. The growth of parental (non-resistant) and trastuzumab-resistant BT474-M3 cell spheroids is shown as % of control (no trastuzumab or MM-111 added) cells (Y-axes) after treatment with a dose range of drug (X-axes, in nM trastuzumab or MM-111).

Figure 12 is two graphs comparing the effect of MM-111 or trastuzumab on cell growth of trastuzumab-resistant BT474-M3 cell spheroids when in combination with 300nM erlotinib (Figure 12A) or 100nM gefitinib (Figure 12B). The growth of the cell spheroids is shown as % of control (dashed line, no drug added). The growth of cell spheroids treated with erlotinib alone or gefitinib alone is shown by dot-dash lines. The x-axes are a log scale of each of MM-111 and/or trastuzumab concentration in nM and the y axis is spheroid size as % of control spheroid size.

Figure 13 is a series of graphs showing the effect of MM-111, lapatinib, and tamoxifen on tumor growth inhibition in a BT474-M3 xenograft model. In Figures 13A, 13B, and 13C, the left panel shows tumor volume of xenografts of BT474-M3 cells that have been engineered to express green fluorescent protein and the right panel shows tumor volume in xenografts of the BT474-M3 cells that have been engineered to express GFP and heregulin 1. Figure 13A shows the tumor growth curves of BT474-M3-GFP and BT474-M3-GFP-HRG tumors wherein the mice were treated with MM-111 (48 mpk), lapatinib (150 mpk) and tamoxifen (5 mg). Figure 13B shows the tumor growth curves of BT474-M3-GFP and BT474-M3-GFP-HRG tumors wherein the mice were treated with MM-111 (48 mpk) + lapatinib (150 mpk), MM-111 + tamoxifen (5 mg), and lapatinib + tamoxifen combination therapies. Figure 13C shows the tumor growth curves of BT474-M3-GFP and BT474-M3-GFP-HRG tumors wherein the mice were treated with lapatinib + tamoxifen and MM-111 + lapatinib + tamoxifen combination therapies. Control mice received no treatment. The x-axes are time in days and the y-axes are tumor volume in relation to the tumor volume at the start of treatment on day 17 or day 20 after

inoculation (“Ratio to D17” or “Ratio to D20”).

Figure 14 is a series of graphs showing the effect of MM-111, lapatinib and tamoxifen mono- and combination therapies on HRG-induced signaling in BT474-M3-GFP (left panels) and BT474-M3-GFP-HRG (right panels) tumors. Figure 14A shows pErbB3 levels in pg/ml; Figure 14B shows total ErbB3 levels (tErbB3) in pg/ml; Figure 14C shows the ratio of phospho-ErbB3 to total ErbB3; Figure 14D shows phospho-Akt (pAkt) levels in pg/ml; Figure 14E shows total Akt levels (tAkt) in pg/ml; Figure 14F shows the ratio of pAkt to tAkt; Figure 14G shows phospho-ERK1/2 levels (pERK) normalized to the levels of proliferating cell nuclear antigen (PCNA); and Figure 14H shows total ERK1/2 levels (totERK) normalized to the levels of PCNA; Figure 14I shows the ratio of pERK and totERK levels. The x-axes represent the therapy the tumor-bearing mice received. Control mice received no treatment.

Figure 15 is a series of graphs showing tumor growth curves in an NCI-N87 xenograft model. Figure 15A shows tumor bearing mice either untreated (control) or treated with trastuzumab (3.5 mpk) + 5-fluorouracil (5-FU; 12 mpk 5 days/week), trastuzumab + 5-FU + cisplatin (5 mpk), 1st line MM-111 (96 mpk) + trastuzumab + 5-FU, 2nd line MM-111 + trastuzumab + 5-FU and 2nd line MM-111 + trastuzumab + 5-FU + cisplatin. The switch to 1st to 2nd line treatments as well as discontinuation of the chemotherapeutics is indicated with arrows. Figure 15B shows the tumor growth curves of NCI-N87 –tumors treated with trastuzumab + 5-FU and 2nd line MM-111 + trastuzumab + 5-FU. Figure 15C shows the tumor growth curves of NCI-N87 –tumors treated with trastuzumab + 5-FU + cisplatin and 2nd line MM-111 + trastuzumab + 5-FU + cisplatin. The x-axes are time in days and the y-axes are tumor volume in mm³.

Figure 16 is a series of graphs showing the effect of MM-111, lapatinib and tamoxifen mono- and combination therapies on HRG-induced signaling in BT474-M3-GFP (left panels) and BT474-M3-GFP-HRG (right panels) tumors. Tumor-bearing mice were treated with MM-111, lapatinib and trastuzumab monotherapies (Figure 16A); MM-111 + lapatinib, MM-111 + trastuzumab, and lapatinib + trastuzumab combination therapies (Figure 16B); or lapatinib + trastuzumab and MM-111 + lapatinib + trastuzumab combination therapies (Figure 16C). The x-axes are time in days and the y-axes are tumor volume in relation to the tumor volume at the start of treatment on day 17 after inoculation (“Ratio”).

Figure 17 is a graph showing tumor growth curves in an NCI-N87 xenograft model. Tumor bearing mice were either untreated (control) or treated with paclitaxel (20 mpk), trastuzumab (3.5 mpk) + paclitaxel, or MM-111 (48 mpk) + trastuzumab + paclitaxel. The x-axis is time in days and the y-axis is tumor volume in mm³.

Detailed Description

Methods for overcoming resistance to ErbB pathway inhibitors are provided, as well as pharmaceutical compositions that can be used in such methods. As described further in the

Examples, it has now been demonstrated that an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody or a bispecific anti-ErbB3, anti-ErbB2 antibody, is able to overcome ligand-induced (e.g., heregulin-induced) resistance to an ErbB pathway-targeted therapy (e.g., an EGFR-targeted therapy) both in vitro and in vivo. Accordingly, provided herein are methods for overcoming resistance to ErbB pathway inhibitors by combining the use of an ErbB pathway inhibitor with an ErbB3 inhibitor.

Although not intended to be limited by mechanism or bound by any theory of operation, the ability of the ErbB3 inhibitors described herein to overcome resistance to ErbB pathway inhibitors is thought to be due, at least in part, to the ability of the ErbB3 inhibitor to block ligand-dependent reactivation of ErbB3 signaling that leads to reactivation of PI3K/AKT signaling.

So that this disclosure may be more readily understood, certain terms are first defined.

As used herein, the term “inhibitor” indicates therapeutic agents that inhibit, downmodulate, suppress or downregulate activity of a receptor or other signal transduction protein, including signaling mediated thereby. The term encompasses small molecule inhibitors (e.g., small molecule tyrosine kinase inhibitors) and antibodies, interfering RNA (shRNA, siRNA), soluble receptors and the like.

An “ErbB pathway inhibitor” is an inhibitor that acts on one or more proteins of one or more ErbB signaling pathways, such as the EGFR (ErbB1/HER1) signaling pathway or the HER2 (ErbB2, neu) signaling pathway.

An “EGFR inhibitor” acts on EGFR.

A “HER2 inhibitor” acts on HER2 (ErbB2).

An “ErbB3 inhibitor” acts on ErbB3.

An “antibody” is a whole antibody or any antigen binding fragment (i.e., “antigen-binding portion”) or single chain thereof. The term “antibody” encompasses: (i) monoclonal antibodies; (ii) recombinant antibodies (i.e., antibodies that are prepared, expressed, created or isolated by recombinant means); (iii) chimeric antibodies (i.e., antibodies in which the variable domain(s) are from one species and the constant domain(s) are from another); (iv) humanized antibodies (i.e., antibodies in which only the CDRs are from a donor species and the rest of the antibody structure is human, although additional FR substitutions, either donor substitutions or non-donor/non-acceptor substitutions, may be incorporated); (v) fully human antibodies (i.e., antibodies in which the variable region CDRs and FRs are derived from human germline immunoglobulin sequences); and (vi) bispecific and multispecific antibodies (i.e., antibodies having two or more binding sites with different antigen-binding specificities). The term “antigen-binding portion” of an antibody (or simply “antibody portion”), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., ErbB3). Examples of binding fragments encompassed within the term “antigen-binding portion” of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the V_L,

V_H, CL and CH1 domains; (ii) a F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the V_H and CH1 domains; (iv) an Fv fragment consisting of the V_L and V_H domains of a single arm of an antibody, (v) a dAb including V_H and V_L domains; (vi) a dAb fragment, which consists of a V_H domain; (vii) a dAb which consists of a V_H or a V_L domain; and (viii) a combination of two or more isolated CDRs which are joined, e.g., by a synthetic linker. Furthermore, although the two domains of the Fv fragment, V_L and V_H, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V_L and V_H regions pair to form a monovalent molecule (known as a single chain Fv (scFv)). Such single chain antibodies are also intended to be encompassed within the term “antigen-binding portion” of an antibody. These antibody fragments may be obtained using conventional techniques known to those with skill in the art, and the fragments may be screened for utility in the same manner as are intact antibodies. Antigen-binding portions can be produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact immunoglobulins.

The term “resistance to an ErbB pathway inhibitor” (such as in “exhibiting resistance to an ErbB pathway inhibitor”) refers to the property of a cell (*e.g.*, a cancer cell) in which the cell displays reduced, diminished or a lack of responsiveness to an ErbB pathway inhibitor (*e.g.*, as measured by the ability of the inhibitor to inhibit cell growth or proliferation), as compared to the same cell at an earlier time point or as compared to other cells of the same type that respond to the ErbB pathway inhibitor. The cell can be within tissue, *e.g.*, tumor tissue. Furthermore, the tissue, *e.g.*, tumor tissue, can be in a subject, in which case the subject is referred to as exhibiting resistance to the ErbB pathway inhibitor.

As used herein, the term “acquired resistance” refers to resistance to an ErbB pathway inhibitor that develops in a cell over time, typically during the course of treatment with an ErbB pathway inhibitor, such that the responsiveness of the cell to the ErbB pathway inhibitor diminishes over time as compared to the responsiveness of such a cell to the inhibitor at the start of treatment. This “acquired resistance”, which develops over time in previously responsive cells, is in contrast to cells that are “predisposed to resistance” to an ErbB pathway inhibitor, which refers to an inherent lack of, or significantly reduced, responsiveness of the cells to treatment with an ErbB pathway inhibitor as compared to cells that exhibit responsiveness to (*i.e.*, cells whose growth and/or proliferation is significantly inhibited by) the ErbB pathway inhibitor.

As used herein, the terms “overcoming resistance” and “overcome resistance” to an inhibitor, *e.g.*, an ErbB pathway inhibitor, refers to the phenomenon in which the level or amount or degree of resistance to an inhibitor in a previously-resistant cell is diminished, reduced or reversed such that the cell exhibits a measurable degree of responsiveness (or

increased responsiveness) to the same inhibitor, or another inhibitor that inhibits the same signaling pathway, as compared to the cell in its resistant state. For example, “overcoming resistance to an EGFR pathway inhibitor” in a cell, wherein the inhibitor for which resistance has been demonstrated is, for example, gefitinib, results in a cell that exhibits a measurable degree of responsiveness to gefitinib or to another EGFR pathway inhibitor (such as the anti-EGFR antibody cetuximab) as compared to the cell in its resistant state.

As used herein, the term “subject” includes any human or nonhuman mammal having a disease or disorder for which resistance to an ErbB pathway inhibitor can be addressed using a method provided herein, such as a subject or patient with a tumor exhibiting such resistance

I. ErbB3 Inhibitors

As described in further detail herein, the methods and compositions provided herein involve the use of one or more ErbB3 inhibitors.

MM-121 is a fully human anti-ErbB3 antibody currently undergoing Phase II clinical trials. MM-121 (also referred to as “Ab #6”) and related human anti-ErbB3 antibodies are described in detail in U.S. Patent No. 7,846,440, U.S. Patent Publication Nos. 20090291085, 20100056761, and 20100266584, and PCT Publication No. WO 2008/100624. Other anti-ErbB3 antibodies that may be used in a disclosed combination include any of the other anti-ErbB3 antibodies described in U.S. Patent No. 7,846,440, such as Ab #3, Ab #14, Ab #17 or Ab #19 or an antibody that competes with Ab #3, Ab #14, Ab #17 or Ab #19 for binding to ErbB3. Additional examples of anti-ErbB3 antibodies that may be administered in accordance with the methods disclosed herein include antibodies disclosed in U.S. Patents and Patent Publications Nos. 7,285,649, 20100310557, and 20100255010, as well as antibodies 1B4C3 (cat # sc-23865, Santa Cruz Biotechnology) and 2D1D12 (U3 Pharma AG), both of which are described in, e.g., U.S. Patent Publication No. 20040197332 and are produced by hybridoma cell lines DSM ACC 2527 or DSM ACC 2517 (deposited at DSMZ) anti-ErbB3 antibodies disclosed in U.S. Patent No. 7,705,130 including but not limited to the anti-ErbB3 antibody referred to as AMG888 (U3-1287 -- U3 Pharma AG and Amgen), described in, e.g., U.S. Patent No. 7,705,130; the anti-ErbB3 antibody referred to as AV-203 (Aveo Pharmaceuticals) which is described in U.S. Patent Publication No. 20110256154, the monoclonal antibodies (including humanized versions thereof), such as 8B8 (ATCC® HB-12070™), described in U.S. Patent No. 5,968,511, and the anti-ErbB3 antibodies mAb 205.10 (e.g., mAb 205.10.1, mAb 205.10.2, or mAb 205.10.3) (Roche-Glycart), described in, e.g., U.S. Patent Publication No. 20110171222. Other such examples include anti-ErbB3 antibodies that are multi-specific antibodies and comprise at least one anti-ErbB3 antibody (e.g., one of the aforementioned anti-ErbB3 antibodies) linked to at least a second therapeutic antibody or to an additional therapeutic agent. Yet other suitable anti-ErbB3 antibodies comprise either: 1) variable heavy (VH) and/or variable light (VL) regions

encoded by the nucleic acid sequences set forth in SEQ ID NOs:45 and 46, respectively, or 2) VH and/or VL regions comprising the amino acid sequences set forth in SEQ ID NOs: 1 and 2, respectively, or 3) CDRH1, CDRH2, and CDRH3 sequences comprising the amino acid sequences set forth in SEQ ID NO:3(CDRH1) SEQ ID NO:4(CDRH2) and SEQ ID NO: 5(CDRH3), and/or CDRL1, CDRL2, and CDRL3 sequences comprising the amino acid sequences set forth in SEQ ID NO: 6 (CDRL1) SEQ ID NO: 7 (CDRL2) and SEQ ID NO: 8 (CDRL3) as well as an antibody that binds to human ErbB3 and has at least 90% variable region sequence identity with the above-mentioned antibodies 1), 2), or 3). In another embodiment, the antibody competes for binding with and/or binds to the same epitope on human ErbB3 as any one of the above-mentioned antibodies. When the antibody is MM-121, the epitope typically comprises residues 92-104 of human ErbB3 (SEQ ID NO: 41). In other embodiments, the antibody is a fully human monoclonal antibody that binds to ErbB3 and, in living cells and either a) inhibits ErbB2/ErbB3 complex formation or b) prevents intracellular phosphorylation of ErbB3 induced by any of the forms of each of the following: heregulin, EGF, TGF α , betacellulin, heparin-binding epidermal growth factor, biregulin, epigen, epiregulin, and amphiregulin, or does both a) and b).

Anti-ErbB3 antibodies described above, can be generated, e.g., in prokaryotic or eukaryotic cells, using methods well known in the art, e.g., in a cell line capable of glycosylating proteins, such as CHO cells.

MM-111 (also referred to as B2B3-1), is described in co-pending U.S. Patent Application Serial No. 12/757,801, and PCT Publication No. WO2009/126920. Also disclosed therein are other bispecific anti-ErbB2/antiErbB3 antibodies that are scFv HSA conjugates and that are suitable for use in the methods and compositions provided herein, including A5-HSA-ML3.9, A5-HSA-B1D2, B12-HSA-B1D2, A5-HSA-F5B6H2, H3-HSA-F5B6H2, and F4-HSA-F5B6H2. Other bispecific anti-ErbB2/antiErbB3 antibodies that are suitable for use in the methods and compositions provided herein include ALM and H3 x B1D2, each comprising an anti-ErbB3 antibody linked to an anti-ErbB2 antibody, which are described further in U.S. Patent Nos. 7,332,585 and 7,332,580, as well as in PCT Application Serial No. PCT/US2007/024287.

In yet another embodiment, the bispecific anti-ErbB3, anti-ErbB2 antibody can comprise a mixture, or cocktail, of two or more bispecific anti-ErbB3, anti-ErbB2 antibodies, each of which binds to a different epitope on ErbB3. In one embodiment, the mixture, or cocktail, comprises three bispecific anti-ErbB3, anti-ErbB2 antibodies, each of which binds to a different epitope on ErbB3.

In another embodiment, the ErbB3 inhibitor comprises a nucleic acid molecule, such as an RNA molecule, that inhibits the expression or activity of ErbB3. RNA antagonists of ErbB3 have been described (see e.g., U.S. Patent Publication No. 20080318894). Moreover, interfering

RNAs specific for ErbB3, such as shRNAs or siRNAs that specifically inhibit the expression and/or activity of ErbB3, have been described (see e.g., Sergina, N.V. et al. (2007) *Nature* 445:437-441; Liu, B. et al. (2007) *Int. J. Cancer* 120:1874-1882; Frolov, A. et al. (2007) *Cancer Biol. Ther.* 6:548-554; Sithanandam, G. and Anderson, L.M. (2008) *Cancer Gene Ther.* 15:413-418; Lee-Hoeflich, S.J. et al. (2008) *Cancer Res.* 68:5878-5887).

In yet another embodiment, the ErbB3 inhibitor comprises a soluble form of the ErbB3 receptor that inhibits signaling through the ErbB3 pathway. Such soluble ErbB3 molecules have been described in the art (see e.g., U.S. Patent No. 7,390,632, U.S. Patent Publication No. 20080274504 and U.S. Patent Publication No. 20080261270, each by Maihle et al., and U.S. Patent Publication No. 20080057064 by Zhou).

In another embodiment, the ErbB3 inhibitor comprises a nucleic acid molecule, such as an RNA molecule, that inhibits the expression or activity of ErbB3. RNA antagonists of ErbB3 have been described (see e.g., U.S. Patent Publication No. 20080318894). Moreover, interfering RNAs specific for ErbB3, such as shRNAs or siRNAs that specifically inhibit the expression and/or activity of ErbB3, have been described (see e.g., Sergina, N.V. et al. (2007) *Nature* 445:437-441; Liu, B. et al. (2007) *Int. J. Cancer* 120:1874-1882; Frolov, A. et al. (2007) *Cancer Biol. Ther.* 6:548-554; Sithanandam, G. and Anderson, L.M. (2008) *Cancer Gene Ther.* 15:413-418; Lee-Hoeflich, S.J. et al. (2008) *Cancer Res.* 68:5878-5887).

In yet another embodiment, the ErbB3 inhibitor comprises a soluble form of the ErbB3 receptor that inhibits signaling through the ErbB3 pathway. Such soluble ErbB3 molecules have been described in the art (see e.g., U.S. Patent No. 7,390,632, U.S. Patent Publication No. 20080274504 and U.S. Patent Publication No. 20080261270, each by Maihle et al., and U.S. Patent Publication No. 20080057064 by Zhou).

II. ErbB Pathway Inhibitors

As described in further detail herein, the methods and compositions provided herein involve the use of one or more ErbB pathway inhibitors.

In one embodiment, the ErbB pathway inhibitor is an EGFR inhibitor (i.e., an inhibitor that inhibits EGFR and thereby inhibits EGFR pathway signaling).

In one embodiment, the EGFR inhibitor comprises an anti-EGFR antibody. One A useful anti-EGFR antibody is cetuximab (Erbix®, ImClone). Other examples of anti-EGFR antibodies include MM-151 (further described in Bukhalid et al., co-pending commonly assigned U.S. Patent Application Serial No. 61/504,633, filed on July 5, 2011), Sym004 (Symphogen, Pederson et al., *Cancer Research* January 15, 2010 **70**: 588, also see U.S. Patent Serial No. 7,887,805), matuzumab (EMD72000), panitumumab (Vectibix®; Amgen); nimotuzumab (TheraCIM) and mAb 806 (Mishima, K. et al. (2001) *Cancer Res.* 61:5349-5354).

In another embodiment, the EGFR inhibitor comprises a small molecule inhibitor of the EGFR signaling pathway, such as a tyrosine kinase inhibitor (TKI) that inhibits the EGFR signaling pathway. An example of a small molecule inhibitor of the EGFR signaling pathway is gefitinib (Iressa®, AstraZeneca and Teva). Other examples of small molecule inhibitors of EGFR include erlotinib HCL (OSI-774; Tarceva®; OSI Pharma), lapatinib (Tykerb®, GlaxoSmithKline), canertinib (PD183805; Pfizer), PKI-166 (Novartis); PD158780; pelitinib; and AG 1478 (4-(3-Chloroanilino)-6,7-dimethoxyquinazoline).

In another embodiment, the ErbB pathway inhibitor is a HER2 inhibitor (*i.e.*, an inhibitor that inhibits HER2 pathway signaling).

In one embodiment, the HER2 inhibitor comprises an anti-HER2 antibody. An example of an anti-HER2 antibody is trastuzumab (Herceptin®). Herceptin is commercially available from Genentech, Inc. Another example of an anti-HER2 antibody is pertuzumab (Omnitarg®; Genentech).

In another embodiment, the HER2 inhibitor comprises a small molecule inhibitor of the HER2, such as a tyrosine kinase inhibitor (TKI) that inhibits HER2 signaling. Non-limiting examples of small molecule inhibitors of HER2 signaling include lapatinib (Tykerb®, GlaxoSmithKline), CI-1033 (PD 183805; Pfizer), PKI-166 (Novartis) and pelitinib EKB-569.

III. Methods

In one aspect, a method is provided for overcoming resistance to an ErbB pathway inhibitor in a subject, the method comprising:

- selecting a subject exhibiting resistance to an ErbB pathway inhibitor; and
- administering to the subject (i) an ErbB3 inhibitor and (ii) an ErbB pathway inhibitor.

The ErbB pathway inhibitor administered to the subject does not need to be the same ErbB pathway inhibitor to which the subject has been demonstrated to be resistant, although typically, the ErbB pathway inhibitor administered to the subject will be directed against the same ErbB pathway as the ErbB pathway inhibitor to which the subject has been demonstrated to be resistant. For example, a subject who exhibits resistance to the EGFR pathway inhibitor gefitinib may be co-administered an ErbB3 inhibitor and an EGFR inhibitor, which EGFR inhibitor can be, for example, gefitinib or the anti-EGFR antibody cetuximab.

The ErbB3 inhibitor and the ErbB pathway inhibitor can be co-administered to the subject or, alternatively, the ErbB3 inhibitor can be administered prior to administration of the ErbB pathway inhibitor. The ErbB3 inhibitor and the ErbB pathway inhibitor can be administered to the subject by any route suitable for the effective delivery of the inhibitor to the subject. For example, many small molecule inhibitors are suitable for oral administration. Antibodies and other biologic agents typically are administered intravenously, intraperitoneally or intramuscularly.

Identification of a subject exhibiting resistance to an ErbB pathway inhibitor can be achieved through standard methods well known in the art. For example, the inability (or reduced ability) of the ErbB pathway inhibitor to inhibit the growth and/or proliferation of tumor cells in the subject (or a sample of tumor cells from the subject cultured *in vitro*) can be indicative of resistance.

In some embodiments, the resistance to the ErbB pathway inhibitor is acquired resistance, e.g., acquired resistance to an EGFR inhibitor, e.g., acquired resistance to gefitinib. In another embodiment, the acquired resistance to an EGFR inhibitor is associated with a T790M EGFR mutation in the subject, e.g., in a tumor in the subject. In another embodiment, the acquired resistance is to a HER2 inhibitor.

The resistance exhibited by the subject may be resistance associated with reactivation of PI3K/AKT signaling and the ErbB3 inhibitors inhibit PI3K/AKT signaling. Methods for assessing the ability of an ErbB3 inhibitor to inhibit PI3K/AKT signaling are known in the art, such as the assays described in detail in the Examples. For example, the ability of the ErbB3 inhibitor to inhibit phosphorylation of AKT can be assessed using standard techniques known in the art.

In another embodiment, the ErbB3 inhibitor administered to the subject is an anti-ErbB3 antibody. A useful anti-ErbB3 antibody comprises MM-121, comprising V_H and V_L sequences as shown in SEQ ID NOs: 1 and 2, respectively, or an antibody comprising V_H CDR1, 2 and 3 sequences as shown in SEQ ID NOs: 3-5, respectively, and V_L CDR1, 2 and 3 sequences as shown in SEQ ID NOs: 6-8, respectively (i.e., the V_H and V_L CDRs of MM-121). In another embodiment, the anti-ErbB3 antibody is an antibody having heavy and light chains comprising the amino acid sequences set forth in SEQ ID NOs 42 and 43, respectively. Additional non-limiting exemplary anti-ErbB3 antibodies and other forms of ErbB3 inhibitors are described in detail in Subsection I above.

In another embodiment, the ErbB pathway inhibitor administered to the subject is an EGFR inhibitor. A useful EGFR inhibitor is an anti-EGFR antibody, e.g., cetuximab. Additional non-limiting exemplary anti-EGFR antibodies are described in detail in Subsection II above.

In another embodiment, the ErbB pathway inhibitor administered to the subject is a small molecule inhibitor of EGFR signaling as described in Subsection II above. A useful small molecule inhibitor of EGFR signaling is gefitinib. Additional non-limiting exemplary small molecule inhibitors of EGFR signaling are described in detail in Subsection II above.

In yet another embodiment, the ErbB pathway inhibitor administered to the subject is a HER2 inhibitor. Useful HER2 inhibitors include lapatinib and anti-HER2 antibodies, e.g., trastuzumab. Additional non-limiting exemplary anti-HER2 inhibitors are described in detail in Subsection II above.

In another aspect, a method of inhibiting growth, invasiveness or metastasis of a tumor is provided, wherein the tumor comprises cells comprising a T790M EGFR mutation, the method comprising contacting the tumor (or cells thereof) with (i) an EGFR inhibitor; and (ii) an ErbB3 inhibitor.

In certain embodiments, the ErbB3 inhibitor inhibits PI3K/AKT signaling. Methods for assessing the ability of an ErbB3 inhibitor to inhibit PI3K/AKT signaling are known in the art, such as the assays described in detail in the Examples. For example, the ability of the ErbB3 inhibitor to inhibit phosphorylation of AKT can be assessed using standard techniques known in the art.

In one embodiment, the tumor (or cells thereof) is contacted with an ErbB3 inhibitor comprising an anti-ErbB3 antibody as described in detail in Subsection I above.

In another embodiment, the tumor (or tumor cells) is contacted with an EGFR inhibitor comprising an anti-EGFR antibody as described in detail in Subsection II above. In another embodiment, the tumor (or tumor cells) is contacted with an EGFR inhibitor comprising a small molecule inhibitor of EGFR signaling, as described in detail in Subsection II above.

In yet another aspect, a method of treating a tumor in a subject is provided, the method comprising

selecting a subject with a tumor comprising a T790M EGFR mutation, and
administering to the subject (i) an EGFR inhibitor; and (ii) an ErbB3 inhibitor.

The ErbB3 inhibitor and the EGFR inhibitor can be co-administered to the subject or, alternatively, the ErbB3 inhibitor can be administered prior to administration of the EGFR inhibitor. The ErbB3 inhibitor and the EGFR inhibitor can be administered to the subject by any route suitable for the effective delivery of the inhibitor to the subject. For example, many small molecule inhibitors are suitable for oral administration. Antibodies and other biologic agents typically are administered intravenously, intraperitoneally or intramuscularly.

Identification of a subject with a tumor comprising a T790M EGFR mutation can be achieved using methods well known in the art, such as by analysis (e.g., by PCR and sequencing) of genomic DNA in, or cDNA encoding EGFR prepared from, a sample of tumor cells (e.g., a biopsy) from the subject.

A useful ErbB3 inhibitor is one that inhibits PI3K/AKT signaling. Methods for assessing the ability of an ErbB3 inhibitor to inhibit PI3K/AKT signaling are well known in the art, such as the assays described in detail in the Examples.

The ErbB3 inhibitor administered to the subject may comprise an anti-ErbB3 antibody, e.g., MM-121, which comprises V_H and V_L sequences as shown in SEQ ID NOs: 1 and 2, respectively, or the ErbB3 inhibitor may be an antibody comprising V_H CDR1, 2 and 3 sequences as shown in SEQ ID NOs: 3-5, respectively, and V_L CDR1, 2 and 3 sequences as shown in SEQ ID NOs: 6-8, respectively (i.e., the V_H and V_L CDRs of MM-121). Additional

non-limiting exemplary anti-ErbB3 antibodies and other forms of ErbB3 inhibitors are described in detail in Subsection I above.

In another embodiment, the EGFR inhibitor administered to the subject comprises an anti-EGFR antibody as described in detail in Subsection II above. In another embodiment, the EGFR inhibitor administered to the subject comprises a small molecule inhibitor of EGFR signaling as described in detail in Subsection II above.

The methods disclosed herein are suitable for use in overcoming resistance to ErbB pathway inhibitors in essentially any diseases or disorders in which such resistance is observed, although the disease for which the methods are used is typically a cancer. In situations in which the resistance is to an EGFR inhibitor, the cancer typically is selected from the group consisting of lung cancer (*e.g.*, non-small cell lung cancer), colorectal cancer, head and neck cancer and pancreatic cancer. In situations in which the resistance is to a HER2 inhibitor, the cancer typically is breast cancer.

IV. Pharmaceutical Compositions

In another aspect, pharmaceutical compositions are provided that can be used in the methods provided herein, *i.e.*, pharmaceutical compositions for overcoming resistance to an ErbB pathway inhibitor. The pharmaceutical compositions typically comprise an ErbB3 inhibitor (as described in detail in Section I above), an ErbB pathway inhibitor (as described in detail in section II above) and a pharmaceutical carrier. The ErbB3 inhibitor and the ErbB pathway inhibitor can be formulated with the pharmaceutical carrier into a single composition. Alternatively, the ErbB3 inhibitor can be formulated with a pharmaceutical carrier to form a first composition, the ErbB pathway inhibitor can be formulated with a pharmaceutical carrier to form a second composition, and the first and second composition can be packaged together. Additionally, the pharmaceutical composition can include, for example, instructions for use of the composition to overcome resistance to an ErbB pathway inhibitor.

As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, and other excipients that are physiologically compatible. Preferably, the carrier is suitable for parenteral, oral, or topical administration. Depending on the route of administration, the active compound, *e.g.*, small molecule or biologic agent, may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.

Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion, as well as conventional excipients for the preparation of tablets, pills, capsules and the like. The use of such media and agents for the formulation of pharmaceutically active substances is known in the art. Except insofar as any conventional media or agents are incompatible with the active

compound, use thereof in the pharmaceutical compositions disclosed herein is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutically acceptable carrier can include a pharmaceutically acceptable antioxidant. Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions disclosed herein include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. In many cases, it will be useful to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.

These compositions may also contain functional excipients such as preservatives, wetting agents, emulsifying agents and dispersing agents.

Therapeutic compositions typically must be sterile, non-pyrogenic, and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by sterilization, *e.g.*, by microfiltration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, exemplary methods of preparation are vacuum drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Prevention of presence of microorganisms may be ensured both by sterilization procedures, *supra*, and by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like.

Pharmaceutical compositions disclosed herein can also be administered combination with other agents besides the ErbB3 inhibitors and ErbB pathway inhibitors described herein.

For example, the combination therapy can include a combination of an ErbB3 inhibitor and an ErbB pathway inhibitor and at least one or more additional therapeutic agents, such as one or more chemotherapeutic agents known in the art. The pharmaceutical compositions and combinations thereof disclosed herein can also be administered in conjunction with radiation therapy and/or surgery.

Dosage regimens are adjusted to provide the optimum desired response (*e.g.*, a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.

It is especially advantageous to formulate parenteral compositions disclosed herein in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

Actual dosage levels of the active ingredients in the pharmaceutical compositions provided herein may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.

The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.

When compounds provided herein are administered as pharmaceuticals, to humans or animals, they can be given alone or as a pharmaceutical composition containing, for example, 0.001 to 90% (*e.g.*, 0.005 to 70% or 0.01 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.

The following examples should not be construed as further limiting the above disclosure. Each and every patent application and publication and issued patent cited herein is incorporated herein by reference in its entirety.

Examples

Part I: Use of anti-ErbB3 Antibodies for Overcoming Resistance to ErbB Pathway Inhibitors

Example 1: MM-121 Blocks Ligand Induced Activation of ErbB3

In this example, the ability of the anti-ErbB3 monoclonal antibody MM-121 (Ab #6, as disclosed in U.S. Patent No. 7,846,440) to inhibit ligand-induced activation of ErbB3 phosphorylation and signaling was examined in a series of *in vitro* experiments.

In Vitro Signaling Studies Measured by ELISA

In the first set of experiments, three cancer cell lines (ACHN (renal cell adenocarcinoma, ATCC® #CRL-1611™), Du145 (prostate carcinoma, ATCC® #HTB-81™) and OvCAR 8 (ovarian adenocarcinoma, ATCC® #HTB-161™) cell lines; obtained from the National Cancer Institute's Developmental Therapeutics Program) were seeded at 35,000 cells per well in 96-well plates and grown overnight (maintenance culture medium was RPMI-1640 media supplemented with 10% fetal calf serum, 2mM L-glutamine, and Pen-Strep; cells were grown in a humidified atmosphere at 5% CO₂, 95% air at 37° C). Cells were synchronized by 20-24 hour serum starvation. The cells were then pre-incubated with 4-fold serial dilutions, ranging from 2 mM to 7.6 pM, of MM-121 for 30 minutes. The cells then were stimulated with 25 nM heregulin (HRG)-1beta for 10 minutes, washed once with cold PBS and lysed in MPER lysis buffer (Pierce Chemical Co.).

For ELISA analysis of cell lysates, capture antibodies against ErbB1 (R&D Systems AF231), ErbB2 (R&D Systems, MAB1129), ErbB3 (R&D Systems, MAB 3481) and AKT (Upstate, 05-591MG) were incubated in 384 well black flat-bottom polystyrene high-binding plates (Corning, 3708) overnight at room temperature. ELISAs were blocked with 2% bovine serum albumin (BSA) in phosphate buffered saline (PBS) for one hour and then incubated with lysates diluted in 2% BSA, 0.1% Tween-20 and PBS for two hours at room temperature. Between incubation steps, plates were washed three times with 0.5% Tween-20 in PBS. ELISAs measuring phospho-ErbB1, -ErbB2 and -ErbB3 were incubated with phosphor-tyrosine horseradish peroxidase (HRP) linked monoclonal antibody (R&D Systems, HAM1676) for two hours. ELISAs measuring phosphor-AKT were incubated with primary serine 473 specific anti-phospho AKT mouse monoclonal antibody (Cell Signaling Technologies, 5102) for two hours, then incubated with streptavidin-HRP (DY998) for 30 minutes. All ELISAs were visualized with SuperSignal® ELISA Pico Chemiluminescent Substrate (Pierce, Cat. #37069) and luminescent signal was measured using a luminometer.

ELISA analysis of the cell lysates is summarized in the graphs shown in Figure 1. The data demonstrate that MM-121 inhibits HRG-induced ErbB3, AKT and ERK phosphorylation in comparison to the 25 nM HRG control without MM-121. Inhibitor IC₅₀ values were calculated

by least-squares fitting the dose response data with a sigmoidal curve (GraphPad Prism®, GraphPad Software, Inc., La Jolla, CA). In most cases, maximal inhibition of pErbB3, pAKT and pERK with MM-121 occurred near or below basal signaling levels as measured by the unstimulated control cells. Thus, the results of Figure 1 demonstrate that in ACHN, Du145 and OvCAR8 cells, MM-121 blocked the capacity of heregulin to stimulate ErbB3 and downstream AKT and ERK phosphorylation and reduced signaling levels to equal or below the unstimulated cells. **Example 2: MM-121 Overcomes Resistance to Erlotinib in *In-Vitro* Models of EGFR-Wild-Type Non-Small Cell Lung Cancer**

Methods

Nine non-small cell lung cancer (NSCLC) cell lines were obtained from the American Type Culture collection: A549 (ATCC® #CCL-185™), EKVX (NCI vial 0502454), NCI-H2170 (ATCC® #CRL-5928™), NCI-H2347 (ATCC® #CRL-5942™), NCI-H322M (ATCC® #CRL-5806™), NCI-H358 (ATCC® #CRL-5806™), NCI-H441 (ATCC® #HTB-174™), NCI-H661 (ATCC® #HTB-183™) and SW-900 (ATCC® #HTB-59™). The cell lines bear no mutations within their EGFR genes and represent three distinct histological subtypes (see Table X below). Cells harboring Ras mutations are indicated.

Cells were seeded at 5,000 cells per well in a 96-well 3D-culture system (low-binding NanoCulture® plates, Scivax Corporation) and grown in RPMI-1640 medium supplemented with 10% fetal bovine serum and Pen-Strep at 37 °C. 48 h later, after which time spheroids had formed, serum was reduced to 2% and cells were incubated with ligands and drugs for 6 days at 37 °C. Relative live cell densities were then determined using the CellTiter Glo® reagent (Promega).

Two sets of experiments were performed: in one set, cells were treated with EGF (10 nM), heregulin1-β1 (HRG, 10 nM), a pool of the two ligands (10 nM each ligand), or in the absence of exogenous ligands, as well as with erlotinib (1 μM), MM-121 (1 μM), a combination of the two drugs (1 μM each drug), or in the absence of drugs. In a second set of experiments, cells were treated with doses of erlotinib ranging from 0 to 10 μM, in either the absence or presence of 10 nM heregulin -1β1, and in either the absence or presence of 1 μM MM 121.

Table 1. EGFR wild-type NSCLC cell lines

Cell Line	EGFR mutation status	K-Ras/H-Ras/N-Ras mutation status	Histological subtype
A549	wild-type	K-Ras G12S	adenocarcinoma
EKVX	wild-type	WT	adenocarcinoma
H2170	wild-type	WT	squamous cell carcinoma
H2347	wild-type	N-Ras Q61R	adenocarcinoma
H322M	wild-type	WT	adenocarcinoma
H358	wild-type	K-Ras G12C	adenocarcinoma
H441	wild-type	K-Ras G12V	adenocarcinoma

H661	wild-type	WT	large cell carcinoma
SW-900	wild-type	K-Ras G12V	squamous cell carcinoma

Results

Erlotinib (Tarceva®) is indicated for treatment of patients with non-small cell lung cancer and has been shown to be effective in patients with tumors harboring EGFR mutations; however, patients with tumors having wild-type EGFR show poor response rates to erlotinib in the clinic, and some patients on EGFR therapy develop resistance due to a new T790M mutation appearing (Hammerman *et al.*, (2009) *Clinical Cancer Research* **15**(24), 7502-7509. *In vitro*, EGFR wild-type NSCLC cell lines are substantially less sensitive to erlotinib, having GI₅₀'s several orders of magnitude higher than cell lines bearing EGFR-activating mutations. Activating mutations in Ras oncogenes (H-, N-, and K-Ras) have also been shown to be associated with lung cancer, particularly K-Ras mutations in lung adenocarcinomas. NSCLC subtypes other than adenocarcinoma are also found to correlate with poor response to erlotinib in clinical trials.

In order to demonstrate the effectiveness of MM-121 in overcoming resistance to erlotinib in EGFR wild-type NSCLC cells having multiple histological subtypes, MM-121 was tested in nine EGFR wild-type NSCLC cell lines having adenocarcinoma, squamous cell carcinoma, or large cell carcinoma histological subtypes. The cell lines are either wild-type for the Ras oncogene or harbor K-Ras or N-Ras mutations as indicated in Table 1.

Five cell lines were each grown as spheroids and treated as described above with epidermal growth factor (EGF), heregulin1-β1 (HRG), a pool of ligands (EGF + HRG), or no exogenous ligands (medium), as well as with erlotinib, MM-121, a combination of erlotinib and MM-121, or no drug treatment. Tumor size was then determined by measuring live cell density. As shown in Figure 2, erlotinib inhibited cell growth in the absence of exogenous ligands and in the presence of EGF, but was less effective at inhibiting growth of cells grown in the presence of HRG. While the combination of MM-121 and erlotinib was in some cell lines more effective at inhibiting cell growth in the EGF-stimulated cells, MM-121 was able to greatly improve sensitivity of the cells to erlotinib in HRG-stimulated cells. This was true for all cell spheroids tested, including adenocarcinoma cell lines NCI-H322M, Figure 2A; EKVX, Figure 2B; A549, Figure 2C; H358, Figure 2D, and squamous cell line SW-900, Figure 2E. The mutation state of the K-Ras gene did not impact the effectiveness of MM-121 in increasing sensitivity of the cells to erlotinib.

Eight cell lines were then each grown as spheroids as described above and treated with doses of erlotinib ranging from 0 to 10 μM, in either the absence or presence of heregulin-1β1 (HRG), and in either the absence or presence of MM 121. As shown in Figure 3, while erlotinib was not able to inhibit cell growth in HRG-stimulated cells except at high concentrations; however, addition of MM-121 was able to restore sensitivity of the spheroids to erlotinib in the

presence of HRG. This was true for all cell spheroids tested, including adenocarcinoma cell lines NCI-H322M (Figure 3A); EKVX (Figure 3B); A549 (Figure 3C); NCI-H358 (Figure 3D); NCI-H441 (Figure 3E), NCI-H2347 (Figure 3F); the squamous cell carcinoma cell line NCI-H2170 (Figure 3G), and the large cell carcinoma cell line NCI-H661 (Figure 3H). The mutation state of the K-Ras gene did not affect the effectiveness of MM-121 in increasing sensitivity of the cells to erlotinib.

These results demonstrate that HRG-mediated signaling may play a part in resistance to erlotinib in EGFR wild-type cells. The data further demonstrate that MM-121 is effective in restoring sensitivity of tumor cells to erlotinib in combination therapy.

Example 3: Inhibition of pAKT production in human ovarian cancer cells *in vitro*

Materials and Methods:

The A2780 human ovarian cancer cell line was originally established from tumor tissue from an untreated patient. The A2780cis cell line is cisplatin-resistant (Cat. # 93112517, Sigma). It was developed by chronic exposure of the parent cisplatin-sensitive A2780 cell line (Cat. # 93112519, Sigma) to increasing concentration of cisplatin. A2780cis is cross-resistant to melphalan, adriamycin and irradiation. In order to maintain resistance, cisplatin is added to the culture media every 2-3 passages, post-attachment.

Resistance to cisplatin is confirmed by treating A2780 and A2780cis cells for 72 hours with a serial dilution of cisplatin (0.01 to 10 μ M). Cell viability is measured using the Cell Titer Glo assay (Cat. # G7570, Promega) according to the manufacturer's instructions.

The effect of cisplatin on the AKT pathway is determined by treating sensitive (A2780) and resistant (A2780cis) cells with a dose range of cisplatin (0.1 to 10 μ M) *in vitro* for 1, 4, 24 or 72 hours. After incubation cell lysates are prepared and analyzed for pAKT (ser473) (Cat # 9271 Cell Signaling Technologies) by western blot.

The effect of MM-121 on the AKT pathway is determined by treating sensitive (A2780) and resistant (A2780cis) cells with a dose range of MM-121 ((0.01 to 1 μ M) *in vitro* for 1, 4, 24 or 72 hours. After incubation cell lysates are prepared and analyzed for pAKT (ser473) (Cat. # 9271 Cell Signaling Technologies) by western blot.

Results:

Resistance of the cell line A2780cis to treatment to cisplatin was evaluated by the methods described above or minor variations thereof. Resistant A2780cis and sensitive A2780 cells were plated and treated for 72 hours *in vitro* with a serial dilution of cisplatin (0.01 to 10 μ M). Cell viability was measured by the Cell Titer Glo assay which measures metabolically active cells by quantitating ATP. As shown in Figure 4, the A2780cis cells had a much greater viability (shown as percentage of media control) than did the sensitive line, A2780.

In order to characterize the effect of cisplatin on the AKT pathway *in vitro*, A2780 and A2780cis cells were treated with a dose range of cisplatin as described above for 1, 4 (A2780cis

only), 24, or 72 hours. Cells sensitive to cisplatin showed a decrease in pAKT production (Figure 8A) especially after 24 hours of treatment and/or at high cisplatin concentration (10 μ M), whereas the cisplatin resistant cells showed no effect on pAKT production (figure 8B). As shown in Figure 8C, these cells did show a reduction in AKT phosphorylation after treatment with MM-121. A2780cis cells were treated with a dose range of MM-121 as described above for 1, 4, 24, or 72 hours. Cells showed a gradual decrease in pAKT production at all dose levels and increasing over time.

Example 4: MM-121 rescues cisplatin resistance in a human ovarian cancer cell line *in vitro*

In order to determine whether MM-121 can rescue the cisplatin-resistant phenotype of A2780cis cells *in vitro*, resistant A2780cis and sensitive A2780 cells will be plated as described above and treated with a dose range of cisplatin, MM-121, or a combination thereof for 1, 4, 24, or 72 hours. Cell lysates are analyzed by western blot for pAKT. Cells sensitive to cisplatin will show a reduction in pAKT levels after treatment with cisplatin and MM-121, and an even greater decrease in pAKT for the cells treated with both cisplatin and MM-121. Cells resistant to cisplatin will show no reduction in pAKT after treatment with cisplatin, and a moderate amount of reduction of pAKT after treatment with MM-121. A2780cis cells treated with a combination of MM-121 and cisplatin will show a greater decrease in the amount of pAKT after treatment than cells treated with MM-121 alone, suggesting an additive effect on the inhibition PI3K/AKT signaling and a restoration of sensitivity to cisplatin.

Part II: Use of bispecific anti-ErbB3, anti-ErbB2 Antibodies for Overcoming Resistance to ErbB Pathway Inhibitors

Methods

In vitro breast cancer model

BT474-M3 cells (see Noble, Cancer Chemother. Pharmacol. 2009 64:741-51) are treated with dose ranges of lapatinib, trastuzumab or MM-111 in the presence or absence of 5 nM heregulin. Viable cells are counted following 6 days of treatment. The effect of MM-111 combined with lapatinib or trastuzumab on inhibition of AKT phosphorylation is assessed in heregulin-stimulated BT474-M3 cells across a dose range.

In vivo breast cancer xenograft model

BT474-M3 cells (2×10^7 cells per mice) are inoculated subcutaneously into Nu/Nu immunodeficient mice, which are implanted with an estrogen pellet (0.72mg; 60-day release) one day before the experiment. Tumors are measured after seven days and mice are randomized into four groups: those treated with placebo, MM-111 (66 mg/kg, q7d), lapatinib (150 mg/kg q1d), or a combination of MM-111 and lapatinib. Tumors are measured twice a week and the experiment is ended at day 40. BT474-M3 breast tumor xenograft models are also treated with

MM-111 (3 mg/kg q3d), trastuzumab (1 mg/kg q7d) or a combination of both drugs at these doses.

Development of trastuzumab-resistance cell line

To establish trastuzumab resistant cells, BT474-M3 cells are cultured in RPMI1640 medium with 100nM trastuzumab for six months, and 200nM trastuzumab for two months, and then the dose level is increased to 500nM. Cells are assayed in cell proliferation periodically to check the resistance level to trastuzumab.

Cell proliferation assay

BT474-M3 parental (wild-type) and trastuzumab-resistant cells are plated in 96-well plates (3000 cells/well). After overnight incubation, cells are treated with a series dilution of trastuzumab or MM-111. After five days of treatment, cell viability is measured by WST-1 (Roche, Cat. # 5015944001) according to manufacturer's instructions. Cells treated with control (RPMI1640 with 10% FBS) are set as 100%, other treatments are expressed as percentage of the control.

Flow cytometry analysis

To determine the receptor status on BT474-M3 parental and trastuzumab-resistant cells, cells are trypsinized and washed with FACS buffer. Cells are then incubated with Alexa Fluor® 647-labeled mouse anti-ErbB2 antibody (BioLegend® Cat. # 324412), cetuximab antibody (anti-EGFR), and B12 antibody (anti-ErbB3) for 1 hour at 4°C. Following washing with FACS buffer, cells were analyzed by FACSCalibur™ (BD bioscience).

Spheroid assay

BT474-M3 wild type and trastuzumab-resistant cells (2000 cells/well) are plated in Ultra Low Cluster 96-well plates (Costar®, Corning, NY). After overnight incubation, a series dilution of trastuzumab or MM-111 is introduced to the plate. Cells are cultured for six days. Spheroids are then examined by Nikon microscope and analyzed by MetaMorph® Image Analysis Software (Molecular Devices). The spheroid size from cells cultured in medium containing 10% FBS is set as a control.

Example 5: The activities of Her2-directed agents trastuzumab and lapatinib are attenuated by heregulin stimulated ErbB3 signaling, while MM-111 remains active

The ability of MM-111, lapatinib and trastuzumab to inhibit cell proliferation in the presence of heregulin was tested. Under basal conditions it was found that lapatinib (Figure 6A), trastuzumab (Figure 6B) and MM-111 (Figure 6C) inhibited BT474-M3 cell proliferation by 50%, 32% and 24%, respectively. When cells were cultured in the presence of 5 nM heregulin the effect of both lapatinib and trastuzumab was decreased so that inhibition of cell proliferation was reduced to 23% and 9%, respectively. Conversely, the inhibition of tumor cell growth by MM-111 was retained when heregulin was present, with 33% growth inhibition observed.

Example 6: The addition of MM-111 to lapatinib or trastuzumab increases pAKT inhibition

The ability of the combination of MM-111 and lapatinib or MM-111 and trastuzumab to inhibit AKT phosphorylation (activation) in vivo was investigated. While it was found that lapatinib alone inhibited phosphorylation of AKT in the presence of heregulin, the combination of MM-111 and lapatinib was extremely effective, inhibiting phosphorylation of AKT well below basal levels at therapeutically relevant concentrations (Figure 7A). Trastuzumab did not inhibit AKT phosphorylation following heregulin stimulation (Figure 7B). However, the addition of MM-111 to trastuzumab improved the inhibition of heregulin-stimulated AKT phosphorylation that was observed for trastuzumab alone, with inhibition of pAKT almost to basal levels, suggesting an additive effect of the combination (Figure 7B).

Example 7: The addition of MM-111 to lapatinib or trastuzumab potentiates in vivo activity

The combination of MM-111 with trastuzumab or lapatinib was investigated in vivo using the BT474-M3 breast cancer xenograft model. Sub-optimal monotherapy doses of MM-111 (3 mg/kg dosed every 3 days) and trastuzumab (1 mg/kg dosed weekly), were selected for combination experiments to allow observation of any differences in activity between monotherapy and combination groups. MM-111 administered at 3 mg/kg every 3 days provided similar exposure to a weekly dose of 1 mg/kg trastuzumab due to the different pharmacokinetic properties of each agent in mice. Tumor growth inhibition in groups dosed with the combination of 3 mg/kg MM-111 and 1 mg/kg trastuzumab was more potent, and reached statistical significance, compared to MM-111 alone and trastuzumab alone. Additionally, an increase in the number of completely regressed tumors was observed with combination treatment compared to the monotherapy treatment groups, in which no complete regressions were observed (Figure 8A). MM-111 and lapatinib were each dosed at an optimal efficacious dose weekly and every day, respectively. The combination of MM-111 and lapatinib provided more potency compared to either drug alone (Figure 8B).

Example 8: MM-111 is active in a trastuzumab-resistant cell line

Flow cytometry analysis was performed to determine receptor status in wild-type and trastuzumab-resistant BT474-M3 cell lines. Wild-type or trastuzumab-resistant cells were stained with Alexa Fluor® 647-labeled mouse anti-ErbB2 antibody, cetuximab antibody (anti-EGFR), or B12 antibody (anti-ErbB3). Trastuzumab-resistant cells had a slightly decreased ErbB2 level (Figure 9A) while EGFR (Figure 9B) and ErbB3 (Figure 9C) were unchanged.

To determine the efficacy of MM-111 in inhibiting trastuzumab-resistant BT474-M3 cell proliferation, parental wild-type and trastuzumab-resistant BT474-M3 cells were treated as described above with a series dilution of either MM-111 or trastuzumab. While trastuzumab significantly inhibited cell proliferation in the parental cells, its inhibitory effect was significantly reduced in trastuzumab-resistant cells (Figure 10A). In contrast, MM-111

maintained similar inhibitory activity in both parental and trastuzumab-resistant cells (Figure 10B), thus demonstrating that MM-111 is able to circumvent the resistance mechanisms developed by cells after repeated exposure to trastuzumab.

To further investigate the ability of MM-111 to inhibit cell growth in trastuzumab-resistant cells, multicellular spheroids of parental wild-type and trastuzumab-resistant BT474-M3 cells were prepared using the methods described above or minor variations thereof and treated with a series dilution of either MM-111 or trastuzumab. The inhibitory effect of trastuzumab was diminished in trastuzumab-resistant BT474-M3 cells, although it significantly inhibited spheroid growth of BT474-M3 parental cells (Figure 11A). In contrast, MM-111 significantly reduced spheroid growth of both trastuzumab-resistant and wild-type BT474-M3 cells (Figure 11B). Its inhibitory activity in trastuzumab-resistant cells was slightly improved when compared to its inhibitory activity in wild-type cells.

The data in the preceding Examples demonstrate that MM-111 is effective at inhibiting cell growth in cells that have developed resistance to trastuzumab.

Example 9: MM-111 but not trastuzumab combines with anti-EGFR therapeutics in trastuzumab-resistant BT474-M3 cells

To compare the ability of MM-111 and trastuzumab to inhibit cell growth when in combination with EGFR inhibitors, spheroids of trastuzumab-resistant BT474-M3 cells were prepared using the methods described above and treated with a series of dilution of MM-111 and trastuzumab in the presence of either 300nM erlotinib (Figure 12A) or 100nM gefitinib (Figure 12B). As shown in Figure 12A and 12B, MM-111 but not trastuzumab was able to combine with erlotinib or gefitinib to reduce cell growth in trastuzumab-resistant cell spheroids. These data demonstrate that the combination MM-111 and an EGFR inhibitor is effective at inhibiting cell growth in cells that have developed resistance to trastuzumab. Furthermore, the combination of trastuzumab with an EGFR inhibitor was not sufficient to overcome the resistance of the cells.

Example 10: Combination therapy with MM-111, lapatinib and tamoxifen in BT474-M3 tumor xenografts with and without heregulin

Methods

15x10⁶ BT474-M3 cells engineered to express GFP (BT474-M3-GFP) or BT474-M3 cells engineered to express GFP and heregulin 1 (BT474-M3-GFP-HRG) were implanted in to the mammary fat pads of estrogen supplemented (0.72mg 17 β -estradiol in a 60-day slow release biodegradable carrier) female NCr/NU –mice (Taconic Farms, Inc). When tumor volumes reached on average 516 mm³ (BT474-M3-GFP-HRG on day 17 after tumor implantation) or 422 mm³ (BT474-M3-GFP on day 20 after tumor implantation), mice were segregated into 8 groups of 10-15 mice. Groups received either no treatment (Control), MM-111 (48 mpk q3d i.p. (dose every three days, intraperitoneally)), lapatinib (150 mpk qd p.o. (oral dose daily)), tamoxifen (5mg free base tamoxifen in a 60-day slow release biodegradable carrier), MM-111 and

lapatinib, MM-111 and tamoxifen, lapatinib and tamoxifen or MM-111, lapatinib and tamoxifen. Tumors were measured twice a week with a digital caliper.

At the end of study (21 or 25 days after initiation of treatment for BT474-M3-GFP-HRG and BT474-M3-GFP, respectively) tumor samples were collected (24h after the last MM-111 and 6h after the last lapatinib dose) and analyzed for target and downstream signaling inhibition. Total and phosphorylated ErbB3 and Akt protein levels were analyzed from tumor lysates by suspension array technology (Luminex) and total and phosphorylated Erk1/2 levels by western blot using PCNA to normalize the results.

Results

In order to demonstrate the effectiveness of MM-111 combination therapies to reduce tumor growth of heregulin (HRG) stimulated cells *in vivo*, combination therapies were tested in the BT474-M3-GFP and BT474-M3-GFP-HRG xenograft model according to the methods above. As shown in Figure 13A, BT474-M3-GFP and BT474-M3-GFP-HRG tumor-bearing mice were treated with MM-111 (48 mpk), lapatinib (150 mpk) and tamoxifen (5 mg) monotherapies. Tumoral HRG overexpression improved tamoxifen efficacy and modestly improved MM-111 efficacy. BT474-M3-GFP and BT474-M3-GFP-HRG tumor bearing mice were then treated with MM-111 (48 mpk) + lapatinib (150 mpk), MM-111 + tamoxifen (5 mg), and lapatinib + tamoxifen combination therapies. As shown in Figure 13B, tumoral HRG overexpression modestly improved efficacy of the MM-111 + tamoxifen combination. BT474-M3-GFP and BT474-M3-GFP-HRG tumor bearing mice were then treated with the combination of lapatinib + tamoxifen and MM-111 + lapatinib + tamoxifen combination therapies. As shown in Figure 13C, MM-111 greatly enhanced the efficacy of the lapatinib + tamoxifen combination therapy in both tumor models, demonstrating that MM-111 is required for the maximum anti-tumor efficacy regardless of the tumoral HRG expression.

BT474-M3-GFP and BT474-M3-GFP-HRG tumor bearing mice (Figure 14 left and right panels, respectively) were then treated with (from left to right) control (no treatment), MM-111, lapatinib, and tamoxifen monotherapies, the dual combinations of MM-111 + lapatinib, MM-111 + tamoxifen, and lapatinib + tamoxifen, and the triple combination. As shown in Figure 14A which shows phospho-ErbB3 (pErbB3), tumoral HRG expression increased the ErbB3 phosphoprotein levels and lead to an increased effectiveness of MM-111 monotherapy and MM-111 combination therapy in reducing levels of pErbB3. Tumoral HRG expression lead to a decreased lapatinib and lapatinib + tamoxifen activity in reducing pErbB3 levels. As shown in Figure 14B, MM-111 monotherapy and MM-111 combination therapies increased total ErbB3 expression in both tumor models. As shown in Figure 14C, which shows the ratio of pErbB3 to total ErbB3 (tErbB3), both the MM-111 monotherapy and MM-111 combination therapy decreased ErbB3 activity even in the presence of HRG, whereas lapatinib and lapatinib + tamoxifen effectiveness was reduced in the presence of HRG.

As shown in Figure 14F, which shows the ratio of phospho-Akt (pAkt, Figure 14D) to

total Akt (tAkt or totAkt, Figure 14E), tumoral expression of HRG increased the Akt phosphoprotein/total protein levels and resulted in decreased effectiveness of the lapatinib and lapatinib + tamoxifen therapies, whereas the MM-111 monotherapy and combination therapies were effective at reducing pAkt production in the presence of HRG.

As shown in Figure 14I, which shows the ratio of phospho-ERK (ERKt, Figure 14G) to total Akt (totERK, Figure 14H), tumoral expression of HRG lead to an increase in ERK1/2 phosphoprotein/total protein levels and resulted in decreased effectiveness of the lapatinib and lapatinib + tamoxifen therapies, whereas the MM-111 monotherapy and combination therapies were effective at reducing pERK production in the presence of HRG.

Example 11: MM-111 in combination with the ToGA –regimen in NCI-N87 tumor xenografts

The ToGA Study (Hoffmann-La Roche, ClinicalTrials.gov Identifier NCT01041404) was a study of trastuzumab in combination with chemotherapy compared with chemotherapy alone in patients with HER2-positive advanced gastric cancer. In that study, trastuzumab was administered as intravenous infusion of 6 mg/kg (loading dose 8 mg/kg) every 3 weeks. The chemotherapy consisted of a combination of 6 cycles of fluorouracil (800 mg/m²/day intravenous infusion every 3 weeks) and cisplatin (80 mg/m² intravenous infusion every 3 weeks), or capecitabine (1000 mg/m² p.o. twice daily for 14 days every 3 weeks) and cisplatin (80 mg/m² intravenous infusion every 3 weeks). Treatment with trastuzumab continued until disease progression. This treatment regimen was repeated in an NCI-N87 gastric cancer xenograft model according to the methods below.

Methods

7.5 x 10⁶ NCI-N87 cells (ATCC® # CRL-5822™) were implanted subcutaneously in the flanks of female Nu/Nu (Charles River Laboratories, Inc.) mice. When tumor volumes reached on average 325 mm³ (on day 18 after tumor implantation) mice were segregated into 4 groups of 8-35 mice.

MM-111 was dosed either as a first line therapy at the initial treatment of the mice or as a second line therapy, wherein MM-111 was added to the treatment regimen (see arrows, Figure 15A). Groups received either no treatment (Control), trastuzumab (3.5 mpk q3d i.p.) + 5-FU (12 mpk qd, 5 times per week, i.p.), trastuzumab (3.5 mpk q3d i.p.) + 5-FU (12 mpk qd, 5 times per week, i.p.) + cisplatin (5 mpk q7d i.p.) or 1st line MM-111 (96 mpk q3d i.p.) + trastuzumab (3.5 mpk q3d i.p.) + 5-FU (12 mpk qd, 5 times per week, i.p.). Tumors were measured twice a week with a digital caliber.

At the time of continued tumor growth on day 29, the trastuzumab + 5-FU treatment group was divided into 2 treatment groups receiving either a) trastuzumab + 5-FU or b) 2nd line MM-111 + trastuzumab + 5-FU (see arrow, Day 29). Similarly, at the time of continued tumor growth on day 54, the trastuzumab + 5-FU + cisplatin treatment group was divided into two treatment groups receiving either a) trastuzumab + 5-FU + cisplatin or b) 2nd line MM-111 +

trastuzumab + 5-FU + cisplatin (see arrow, Day 54). Cisplatin administration had to be discontinued on day 52 and 5-FU administration had to be discontinued on day 64 due to animals showing signs of toxicities due to the chemotherapeutics. The discontinuation of the chemotherapies is indicated with arrows Figure 15A.

Results

Figure 15A shows the tumor growth curves of NCI-N87 tumors treated as described above. Figures 15B-D each highlight a subset of the data shown in Figure 15A. As shown in Figure 15B, the addition of MM-111 as a second line therapy given to mice being treated with trastuzumab + 5-FU resulted in an increased efficacy on tumor cell growth inhibition in tumors that had progressed on treatment with trastuzumab + 5-FU alone. Similarly, as shown in Figure 15C, the addition of MM-111 as a second line therapy given to mice being treated with trastuzumab + 5-FU + cisplatin resulted in an increased efficacy on tumor cell growth inhibition in tumors that had progressed (resisted treatment) on treatment with trastuzumab + 5-FU + cisplatin alone. Finally, as shown in Figure 15D, treatment with MM-111 as a first line therapy in combination with trastuzumab and 5-FU prevented tumor growth for the first 60 days of the treatment, in contrast to treatment with the combination of trastuzumab + 5-FU wherein the tumor volume increased from the beginning of the treatment.

Example 12: MM-111 in combination with trastuzumab and paclitaxel in NCI-N87 tumor xenografts

Methods

7.5×10^6 NCI-N87 cells were implanted subcutaneously in the flanks of female Nu/Nu mice. When tumor volumes reached on average 341 mm^3 (on day 24 after tumor implantation) mice were segregated into 4 groups of 10 mice. Groups received either no treatment (Control), paclitaxel (20 mpk q7d i.p.), trastuzumab (3.5 mpk q3d i.p.) + paclitaxel or MM-111 (48 mpk q3d i.p.) + trastuzumab + paclitaxel. Tumors were measured twice a week with a digital caliper.

Results

As shown in Figure 16, the combination of MM-111 with trastuzumab + paclitaxel resulted in an increased efficacy on tumor cell growth inhibition in NCI-N87 tumors and resulted in continued tumor regression in contrast to paclitaxel alone and trastuzumab + paclitaxel, which caused only tumor stasis at best.

Example 13: MM-111/lapatinib/trastuzumab in BT474-M3 ($\pm$ HRG) tumor xenografts

Methods

15×10^6 BT474-M3 cells engineered to express GFP (BT474-M3-GFP) or BT474-M3 cells engineered to express GFP and heregulin 1 (BT474-M3-GFP-HRG) were implanted in to the mammary fat pads of estrogen supplemented (0.72mg 17β -estradiol in a 60-day slow release biodegradable carrier) female NCR/NU mice. When tumor volumes reached on average 286 mm^3 (BT474-M3-GFP-HRG on day 14 after tumor implantation) or 305 mm^3 (BT474-M3-GFP on day 16 after tumor implantation), mice were segregated into 8 groups of 8 mice. Groups

received either no treatment (Control), MM-111 (48 mpk q3d i.p.), lapatinib (150 mpk qd p.o.), trastuzumab (3.5 mpk q3d i.p.), MM-111 + lapatinib, MM-111 + trastuzumab, lapatinib and trastuzumab or MM-111, lapatinib and trastuzumab. Tumors were measured twice a week with a digital caliber.

Results

BT474-M3-GFP and BT474-M3-GFP-HRG tumor bearing mice were treated with MM-111, lapatinib and trastuzumab monotherapies (Figure 17A), MM-111 + lapatinib, MM-111 + trastuzumab, and lapatinib + trastuzumab combination therapies (Figure 17B), and lapatinib + trastuzumab and MM-111 + lapatinib + trastuzumab combination therapies (Figure 17C). As shown in Figure 17B, tumoral HRG overexpression increased the efficacy of the MM-111 + trastuzumab combination and decreased the efficacy of trastuzumab + lapatinib combination.

In addition, as shown in Figure 17C, MM-111 greatly enhanced the efficacy of the lapatinib + trastuzumab combination therapy in the BT474-M3-GFP-HRG tumor model, demonstrating that MM-111 is required for the maximum anti-tumor efficacy when BT474-M3 tumors overexpress heregulin 1.

The results in the preceding Examples demonstrate the effectiveness of MM-111 in combination treatments, both as a 1st line therapy to prevent development of resistance to other therapeutics and a 2nd line therapy to re-sensitize tumor cells to treatment with other therapeutics.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention(s) described herein. Such equivalents are intended to be encompassed by the following claims. Any combination of one or more of the embodiments disclosed in any independent claim and any of the dependent claims is also contemplated to be within the scope of the invention.

Incorporation by Reference

Each and every patent, pending patent application, and publication referred to herein is hereby incorporated herein by reference in its entirety.

SUMMARY OF SEQUENCE LISTING

MM-121 (Ab # 6) V_H amino acid sequence (SEQ ID NO:1)

EVQLLES G GGLVQP G GSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSGGWT
LYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGT LVT
VSS

MM-121 (Ab # 6) V_L amino acid sequence (SEQ ID NO:2)

QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVS WYQQHPGKAPKLIIEVVSQRPSGV
NRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL

MM-121 (Ab # 6) V_H CDR1 (SEQ ID NO:3)

HYVMA

MM-121 (Ab # 6) V_H CDR2 (SEQ ID NO:4)

SISSSGGWTLYADSVKG

MM-121 (Ab # 6) V_H CDR3 (SEQ ID NO:5)

GLKMATIFDY

MM-121 (Ab # 6) V_L CDR1 (SEQ ID NO:6)

TGTSSDVGSYNVVS

MM-121 (Ab # 6) V_L CDR2 (SEQ ID NO:7)

EVSQRPS

MM-121 (Ab # 6) V_L CDR3 (SEQ ID NO:8)

CSYAGSSIFVI

MM-121 Heavy Chain Amino Acid Sequence (SEQ ID NO:42)

1 EVQLLES G GGLVQP G GSLRLSCAASGFTFSHYVMAWVRQA PGKGLEWVSS
51 ISSSGGWTLYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCTRGL
101 KMATIFDYWGQGT LVTVSSA STKGPSVFPLAPCSRSTSES TAALGCLVKD
151 YFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTY
201 TCNVDHKPSN TKVDKTKVERKCCVECP PCA PPVAGPSVFL FPPKPKDTLM
251 ISRTPEVTCV VVDVSHEDPEVQFNWYVDGV EVHNAKTKPR EEQFNSTFRV
301 VSVLTVVHQD WLNKEYKCK VSNKGLPAPI EKTISKTKGQPREPQVYTL P
351 PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPM L DSDG
401 SFFLYSKLTV DKS R WQQGNV FCSVMHEAL HNHYTQKSLS LSPGK

MM-121 Light Chain Amino Acid Sequence (SEQ ID NO:43)

1 QSALTQPASVSGSPGQSITI SCTGTSSDVGSYNVVS WYQQHPGKAPKLI
51 IEVVSQRPSGV SNRFSGSKSGNTASLTISGLQTEDEADYYC CSYAGSSIFV
101 IFGGGTKVTV LGQPKAAPSV TLFPSSSEEL QANKATLVCL VSDFYPGAVT
151 VAWKADGSPV KVG VETTKPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCR V
201 THEGSTVEKT VAPAECS

MM-121 (Ab # 6) Heavy Chain Nucleotide Sequence (SEQ ID NO:45)

gaggtgcagc tgctggagag cggcggaggg ctggtccagc caggcggcag cctgaggctg
tctgcgccg ccagcggcgt caccctcagc cactacgtga tggcctgggt gcggcaggcc
ccaggcaagg gcctggaatg ggtgtccagc atcagcagca gcggcggctg gaccctgtac
gccgacagcg tgaagggcag gttcaccatc agcagggaca acagcaagaa caccctgtac
ctgcagatga acagcctgag ggccgaggac accgccgtgt actactgcac caggggcctg

aagatggcca ccatcttcca ctactggggc cagggcaccc tggtagccgt gagcagc

MM-121 (Ab # 6) Light Chain Nucleotide Sequence (SEQ ID NO:46)

cagtccgccc tgaccagcc cgcagcgtg agcggcagcc caggccagag catcaccatc
agctgcaccg gcaccagcag cgacgtgggc agctacaacg tgggtcctg gtatcagcag
caccgccgca agggcccca gctgatcgc tacgaggtgt cccagaggcc cagcggcgtg
agcaacaggt tcagggcag caagagcggc aacaccgcca gcctgaccat cagcggcctg
cagaccgagg acgaggccga ctactactgc tgcagctacg ccggcagcag catcttcgtg
atcttcggcg gagggaccaa ggtgaccgtc cta

Ab # 3 V_H amino acid sequence (SEQ ID NO:9)

EVQLLES GGGLVQPGGSLRLS CAASGFTFSAYNMRWVRQAPGKGLEWVSVIYPSGGAT
RYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGYYYYGMDVWGQGTLV
TVSS

Ab # 3 V_L amino acid sequence (SEQ ID NO:10)

QSVLTQPPSASGTPGQRVTISCSGSDSNIGRNYIYWYQQFPGTAPKLLIYRNNQRPSGVP
DRISGSKSGTSASLAISGLRSEDEAEYHCGTWDDSLSGPVFGGGTKLTVL

Ab # 3 V_H CDR1 (SEQ ID NO:11)

AYNMR

Ab # 3 V_H CDR2 (SEQ ID NO:12)

VIYPSGGATRYADSVKG

Ab # 3 V_H CDR3 (SEQ ID NO:13)

GYYYYYGMDV

Ab # 3 V_L CDR1 (SEQ ID NO:14)

SGSDSNIGRNYIY

Ab # 3 V_L CDR2 (SEQ ID NO:15)

RNNQRPS

Ab # 3 V_L CDR3 (SEQ ID NO:16)

GTWDDSLSGPV

Ab # 14 V_H amino acid sequence (SEQ ID NO:17)

EVQLLES GGGLVQPGGSLRLS CAASGFTFSAYGMGWVRQAPGKGLEWVSYISPSGGHT
KYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKVLETGLLVDAFDIWGQGT
MTVSS

Ab # 14 V_L amino acid sequence (SEQ ID NO: 18)

QYELTQPPSVSVYPGQTASITCSGDQLGSKFVSWYQQRPGQSPVLVMYKDKRRPSEIPE
RFGSNSNGNTATLTISGTQAIDEADYYCQAWDSSTYVFGTGTKVTVL

Ab # 14 V_H CDR1 (SEQ ID NO:19)

AYGMG

Ab # 14 V_H CDR2 (SEQ ID NO:20)

YISPSGGHTKYADSVKG

Ab # 14 V_H CDR3 (SEQ ID NO:21)
VLETGLLVDAFDI

Ab # 14 V_L CDR1 (SEQ ID NO:22)
SGDQLGSKFVS

Ab # 14 V_L CDR2 (SEQ ID NO:23)
YKDKRRPS

Ab # 14 V_L CDR3 (SEQ ID NO:24)
QAWDSSTYV

Ab # 17 V_H amino acid sequence (SEQ ID NO:25)
EVQLLES GGGLVQPGGSLRLSCAASGFTFSWYGMGWVRQAPGKGLEWVS YISPSGGIT
VYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARLNYYYGLDVWGQGTTVT
VSS

Ab # 17 V_L amino acid sequence (SEQ ID NO:26)
QDIQMTQSPSSLSASVGDRIITTCQASQDIGDSL N WYQQKPGKAPRLLIYDASNLETGVP
PRFSGSGSGTDFTFTFRSLQPEDIATYFCQQSANAPFTFGPGTKVDIK

Ab # 17 V_H CDR1 (SEQ ID NO:27)
WYGMG

Ab # 17 V_H CDR2 (SEQ ID NO:28)
YISPSGGITVYADSVKG

Ab # 17 V_H CDR3 (SEQ ID NO:29)
LNYYYGLDV

Ab # 17 V_L CDR1 (SEQ ID NO:30)
QASQDIGDSL N

Ab # 17 V_L CDR2 (SEQ ID NO:31)
DASNLET

Ab # 17 V_L CDR3 (SEQ ID NO:32)
QQSANAPFT

Ab # 19 V_H amino acid sequence (SEQ ID NO:33)
EVQLLES GGGLVQPGGSLRLSCAASGFTFSRYGMWWVRQAPGKGLEWVS YIGSSGGPT
YYVDSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAGGRGTPYYFDSWGQGT L V
TVSS

Ab # 19 V_L amino acid sequence (SEQ ID NO:34)
QYELTQPASVSGSPGQSITISCTGTSSDIGRWNIVSWYQQHPGKAPKLMYDVS NRPSGV
SNRF

SGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTKLTVL

Ab # 19 V_H CDR1 (SEQ ID NO:35)
RYGMW

Ab # 19 V_H CDR2 (SEQ ID NO:36)
YIGSSGGPTYVDSVKG

Ab # 19 V_H CDR3 (SEQ ID NO:37)
GRGTPYYFDS

Ab # 19 V_L CDR1 (SEQ ID NO:38)
TGTSSDIGRWNIVS

Ab # 19 V_L CDR2 (SEQ ID NO:39)
DVSNRPS

Ab # 19 V_L CDR3 (SEQ ID NO:40)
SSYTSSSTWV

ErbB3 (SEQ ID NO:41)

SEVGNSQAVCPGTLNGLSVTGDAENQYQTLTKLYERCEVVMGNLEIVLTGHNADLSFL
QWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDYGKFAIFVMLNYNTNSSHALRQLR
LTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSCPPCHEVCKGRC
WGPSEDCTLTCTICAPQCNGHCFGNPNPQCCHDECAGGCSGPQDTCFACRHFND
GACVPRCPQPLVYNKLTQLEPNPHTKYQYGGVCVASCNHFVVDQTSCVRACPPDKM
EVDKNGLKMCPECGGLCPKACEGTGSGSRFQTVDSNIDGFVNCTKILGNLDFLITGLNG
DPWHKIPALDPEKLNVFRTVREITGYLNIQSWPPMHNFVFSNLTIGGRSLYNRGFSL
IMKNLNVTSLGFRSLKEISAGRIYISANRQLCYHSLNWTKVLRGPTTEERLDIKHNRPRD
CVAEGKVCPLCSSGGCWGPGPQCLSCRNYSRGGVCVTHCNFLNGEPREFAHEAECFS
CHPECQPMEGTATCNGSGSDTCAQCAHFDRDGPVSSCPHGVLGAKGPIYKYPDVQNEC
RPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTMAITVIAGLVVIFMMLGGTFLYWRGR
RIQNKRAMRRYLERGESIEPLDPSEKANKVLARIFKETELRKLKVLGSGVFGTVHKGWVI
PEGESIKIPVCIKVIDKSGRQSFQAVTDHMLAIGSLDHAHIVRLLGLCPGSSLQLVTQYLP
LGSLLDHVRQHRGALGPQLLNWGVQIAKGMYYLEEHGMVHRNLAARNVLLKSPSQV
QVADFGVADLLPPDDKQLLYSEAKTPIKWMALSIHFGKYTHQSDVWSYGVTVWELMT
FGAEPYAGRLAEVDPDLLEKGERLAQPQICTIDVYVMVMVKCWMIDENIRPTFKELANEFT
RMARDPPRYLVIKRESGPGIAPGPEPHGLTNKKLEEVELEPELDDLDDLEAEEDNLATTTL
GSALSPLVGTLNRPRGSQSLLSPSSGYMPMNQGNLGESQESAVSGSSERCPRPVSLHPMP
RGCLASESSEGHVTGSEAEQEKVSMCRSRSRSPRPRGDSAYHSQRHSLTPVTPLSPPG
LEEEDVNGYVMPDTHLKGTPSSREGTLSSVGLSSVLGTEEEDEDEEYEMNRRRRHSPPHP
PRPSSLEELGYEYMDVGSDLASLGSTQSCPLHPVPIMPTAGTTPDEDYEMNRQRDGGGP
GGDYAAMGACPASEQGYEEMRAFQGPQHAPHVHYARLKTLSLEATDSAFDNPDYWH
SRLFPKANAQRT

MM-111 amino acid sequence (SEQ ID NO:44)

QVQLQESGGGLVKPGGSLRLSCAASGFTSSYWMWVRQAPGKGLEWVANINRDGSA
SYYVDSVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARDRGVGYFDLWGRGTLV
TVSSASTGGGGSGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGYNFVSW
YQQHPGKAPKLMYDVSDRPSGVSDRFSKSGNTASLIISGLQADDEADYYCSSYGSSS

THVIFGGGTKVTVLGAASDAHKSEVAHRFKDLGEENFKALVLI AFAQYLQQSPFEDHV
KLVNEVTEFAKTCVADESAENCDSLHTLFGDKLCTVATLRETYGEMADCCAQEPER
NECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFF
AKRYKAAFTECCQAADKAACLLPKLDEL RDEGKASSAKQRLK CASLQKFGERAFAKAW
AVARLSQRFPKAEFAEVSKLVTDLT KVHTECCHGDLLECADDRADLAKYICENQDSISS
KLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFL
YEYARRHPDYSVVL LRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQ
NCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCKHPEAKRMPC
AEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFQAETF
TFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCKADDKE
TCFAEEGKKLV AASQAALGLAAALQVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWI
AWVRQMPGKGLEYMGLIYPGDSDTKYSPSFQGGQVTISVDKSVSTAYLQWSSLKPSDSA
VYFCARHDVGYCTDRTCAKWPEWLGVWGQGT LVTVSSGGGGSSGGGSGGGGSQSVL
TQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDHTNRPAGVPDRFS
GSKSGTSASLAISGRSEDEADYYCASWDYTL SGWVFGGGTKLTVLG

We claim:

1. A method for overcoming resistance of a tumor in a subject to an ErbB pathway inhibitor, the method comprising:
 - selecting a subject with a tumor exhibiting resistance to an ErbB pathway inhibitor; and
 - administering to the subject (i) an ErbB3 inhibitor and (ii) the ErbB pathway inhibitor.
2. The method of claim 1, wherein the resistance to the ErbB pathway inhibitor is acquired resistance.
3. The method of claim 2, wherein the acquired resistance is acquired resistance to an EGFR inhibitor.
4. The method of claim 3, wherein the acquired resistance is associated with a T790M EGFR mutation in tumor cells.
5. The method of claim 3, wherein the acquired resistance is associated with a KRAS mutation in tumor cells.
6. The method of claim 5, wherein the KRAS mutation is a G12S, G12C, or G12V KRAS mutation.
7. The method of claim 5, wherein the KRAS mutation is a Q61R KRAS mutation.
8. The method of claim 3, wherein the acquired resistance is resistance to gefitinib, trastuzumab, or lapatinib.
9. The method of claim 2, wherein the acquired resistance is acquired resistance to a HER2 inhibitor.
10. The method of claim 1, wherein the resistance is associated with reactivation of PI3K/AKT signaling in tumor cells in the subject.
11. The method of claim 1, wherein the ErbB3 inhibitor administered to the subject is an anti-ErbB3 antibody.
12. The method of claim 1, wherein the ErbB3 inhibitor administered to the subject is a bispecific anti-ErbB3, anti-ErbB2 antibody.

13. The method of claim 11, wherein the anti-ErbB3 antibody comprises V_H and V_L sequences as shown in SEQ ID NOs: 1 and 2, respectively.
14. The method of claim 12, wherein the anti-ErbB3 antibody comprises an antibody comprising V_H CDR1, 2 and 3 sequences as shown in SEQ ID NOs: 3-5, respectively, and V_L CDR1, 2 and 3 sequences as shown in SEQ ID NOs: 6-8, respectively.
15. The method of claim 11, wherein the anti-ErbB3 antibody comprises V_H and V_L sequences as shown in SEQ ID NOs: 9 and 10, respectively.
16. The method of claim 11, wherein the anti-ErbB3 antibody comprises V_H and V_L sequences as shown in SEQ ID NOs: 17 and 18, respectively.
17. The method of claim 11, wherein the anti-ErbB3 antibody comprises V_H and V_L sequences as shown in SEQ ID NOs: 25 and 26, respectively.
18. The method of claim 11, wherein the anti-ErbB3 antibody comprises V_H and V_L sequences as shown in SEQ ID NOs: 33 and 34, respectively.
19. The method of claim 11, wherein the anti-ErbB3 antibody is selected from the group consisting of AV-203, mAb 1B4C3, mAb 2D1D12, AMG-888, mAb 205.10.1, mAb 205.10.2, mAb 205.10.3, and humanized mAb 8B8.
20. The method of claim 1, wherein the ErbB3 inhibitor inhibits PI3K/AKT signaling.
21. The method of claim 1, wherein the ErbB pathway inhibitor is an EGFR inhibitor.
22. The method of claim 21, wherein the EGFR inhibitor is an anti-EGFR antibody.
23. The method of claim 22, wherein the anti-EGFR antibody comprises cetuximab.
24. The method of claim 22, wherein the anti-EGFR antibody is selected from the group consisting of MM-151, Sym004, matuzumab, panitumumab, nimotuzumab and mAb 806.
25. The method of claim 21, wherein the EGFR inhibitor administered to the subject is a small molecule inhibitor of EGFR signaling.

26. The method of claim 25, wherein the small molecule inhibitor of EGFR signaling is gefitinib.
27. The method of claim 25, wherein the small molecule inhibitor of EGFR signaling is selected from the group consisting of lapatinib, canertinib, CI-1033 (PD 183805), erlotinib, PKI-166, PD-158780, pelitinib, EKB-569, and tyrphostin AG 1478.
28. The method of claim 1, wherein the ErbB pathway inhibitor administered to the subject is a HER2 inhibitor.
29. The method of claim 28, wherein the HER2 inhibitor is an anti-HER2 antibody.
30. The method of claim 29, wherein the anti-HER2 antibody is trastuzumab or pertuzumab.
31. The method of any one of claims 1-30, wherein the tumor is a lung cancer.
32. The method of claim 31, wherein the lung cancer is a non-small cell lung cancer (NSCLC).
33. The method of claim 32, wherein the NSCLC is an adenocarcinoma.
34. The method of claim 32, wherein the NSCLC is a squamous cell carcinoma.
35. The method of claim 32, wherein the NSCLC is a large cell carcinoma.
36. The method of any one of claims 1-30, wherein the subject has a cancer selected from the group consisting of colorectal cancer, head and neck cancer, pancreatic cancer and breast cancer.
37. A method of inhibiting growth, invasiveness or metastasis of a tumor, wherein the tumor comprises one or more of a T790M EGFR mutation, a G12S, G12C, or G12V KRAS mutation, and a Q61R KRAS mutation, the method comprising contacting the tumor with (i) an EGFR inhibitor; and (ii) an ErbB3 inhibitor.
38. The method of claim 37, wherein the ErbB3 inhibitor comprises an anti-ErbB3 antibody.
39. The method of claim 37, wherein the ErbB3 inhibitor comprises a bispecific anti-ErbB3, anti-ErbB2 antibody.

40. The method of claim 38, wherein the anti-ErbB3 antibody comprises the V_H and V_L sequences set forth in SEQ ID NOs: 1 and 2, respectively.
41. The method of claim 39, wherein the bispecific anti-ErbB3, anti-ErbB2 antibody comprises the amino acid sequence set forth in SEQ ID NO:44.
42. The method of claim 38, wherein the anti-ErbB3 antibody is selected from the group consisting of mAb 1B4C3, mAb 2D1D12, AMG-888, Av-203, mAb 205.10.1, mAb 205.10.2, mAb 205.10.3, and humanized mAb 8B8.
43. The method of claim 39, wherein the bispecific anti-ErbB3, anti-ErbB2 antibody is selected from the group comprising ALM, A5-HSA-ML3.9, A5-HSA-B1D2, B12-HSA-B1D2, A5-HSA-F5B6H2, H3-HSA-F5B6H2, and F4-HSA-F5B6H2.
44. The method of claim 37, wherein the ErbB3 inhibitor inhibits PI3K/AKT signaling in the tumor.
45. The method of claim 37, wherein the tumor is contacted with an EGFR inhibitor comprising an anti-EGFR antibody.
46. The method of claim 45, wherein the anti-EGFR antibody comprises cetuximab.
47. The method of claim 45, wherein the anti-EGFR antibody is selected from the group consisting of MM-151, Sym004, matuzumab, panitumumab, nimotuzumab and mAb 806.
48. The method of claim 37, wherein the tumor is contacted with an EGFR inhibitor comprising a small molecule inhibitor of EGFR signaling.
49. The method of claim 48, wherein the small molecule inhibitor of EGFR signaling is gefitinib.
50. The method of claim 48, wherein the small molecule inhibitor of EGFR signaling is selected from the group consisting of afatinib, lapatinib, canertinib, erlotinib HCL, pelitinib, PKI-166, PD158780, and tyrphostin AG 1478.
51. The method of any one of claims 37-50, wherein the tumor is a lung cancer tumor.
52. The method of claim 51, wherein the lung cancer is non-small cell lung cancer (NSCLC).

53. The method of claim 51, wherein the NSCLC is an adenocarcinoma.
54. The method of claim 51, wherein the NSCLC is a squamous cell carcinoma.
55. The method of claim 51, wherein the NSCLC is a large cell carcinoma.
56. The method of one of claims 37-50, wherein the tumor is of a cancer selected from the group consisting of colorectal cancer, head and neck cancer, breast cancer, and pancreatic cancer.
57. A method of treating a tumor in a subject, the method comprising selecting a subject with a tumor comprising one or more of a T790M EGFR mutation, a G12S, G12C, or G12V KRAS mutation, and a Q61R KRAS mutation, and administering to the subject (i) an EGFR inhibitor; and (ii) an ErbB3 inhibitor.
58. The method of claim 57, wherein the ErbB3 inhibitor administered to the subject is an anti-ErbB3 antibody.
59. The method of claim 58, wherein the anti-ErbB3 antibody comprises the V_H and V_L sequences set forth in SEQ ID NOs: 1 and 2, respectively.
60. The method of claim 58, wherein the anti-ErbB3 antibody comprises an antibody comprising V_H CDR1, 2 and 3 sequences as shown in SEQ ID NOs: 3-5, respectively, and V_L CDR1, 2 and 3 sequences as shown in SEQ ID NOs: 6-8, respectively.
61. The method of claim 58, wherein the anti-ErbB3 antibody comprises V_H and V_L sequences as shown in SEQ ID NOs: 9 and 10, respectively.
62. The method of claim 58, wherein the anti-ErbB3 antibody comprises V_H and V_L sequences as shown in SEQ ID NOs: 17 and 18, respectively.
63. The method of claim 58, wherein the anti-ErbB3 antibody comprises V_H and V_L sequences as shown in SEQ ID NOs: 25 and 26, respectively.
64. The method of claim 58, wherein the anti-ErbB3 antibody comprises V_H and V_L sequences as shown in SEQ ID NOs: 33 and 34, respectively.

65. The method of claim 58, wherein the anti-ErbB3 antibody is selected from the group consisting of mAb 1B4C3, mAb 2D1D12, AMG-888, AV-203, mAb 205.10.1, mAb 205.10.2, mAb 205.10.3, and humanized mAb 8B8.
66. The method of claim 57, wherein the ErbB3 inhibitor inhibits PI3K/AKT signaling in cells of the tumor.
67. The method of claim 57, wherein the EGFR inhibitor administered to the subject is an anti-EGFR antibody.
68. The method of claim 67, wherein the anti-EGFR antibody comprises cetuximab.
69. The method of claim 67, wherein the anti-EGFR antibody is selected from the group consisting of MM-151, Sym004, matuzumab, panitumumab, nimotuzumab and mAb 806.
70. The method of claim 57, wherein the EGFR inhibitor administered to the subject is a small molecule inhibitor of EGFR signaling.
71. The method of claim 70, wherein the small molecule inhibitor of EGFR signaling is gefitinib.
72. The method of claim 70, wherein the small molecule inhibitor of EGFR signaling is selected from the group consisting of afatinib, lapatinib, canertinib, erlotinib HCL, pelitinib, PKI-166, PD158780, and AG 1478.
73. The method of any one of claims 57-72, wherein the tumor is a lung cancer.
74. The method of claim 73, wherein the lung cancer is a non-small cell lung cancer (NSCLC).
75. The method of claim 74, wherein the NSCLC is an adenocarcinoma.
76. The method of claim 74, wherein the NSCLC is a squamous cell carcinoma.
77. The method of claim 74, wherein the NSCLC is a large cell carcinoma.
78. The method of any one of claims 57-72, wherein the subject has a cancer selected from the group consisting of colorectal cancer, head and neck cancer, breast cancer, and pancreatic cancer.

79. Pharmaceutical compositions for overcoming resistance of a tumor to an ErbB pathway inhibitor, said compositions comprising an ErbB3 inhibitor, an ErbB pathway inhibitor and at least one pharmaceutical carrier.

80. The pharmaceutical compositions of claim 79, wherein the ErbB3 inhibitor and the ErbB pathway inhibitor are formulated with the at least one pharmaceutical carrier into a single composition.

81. The pharmaceutical compositions of claim 79, wherein the ErbB3 inhibitor is formulated with a pharmaceutical carrier to form a first composition, the ErbB pathway inhibitor is formulated with a pharmaceutical carrier to form a second composition, and the first and second composition are optionally packaged together.

82. The pharmaceutical compositions of any one of claims 79-81, wherein the ErbB3 inhibitor is an anti-ErbB3 antibody.

83. The pharmaceutical compositions of claim 82, wherein the ErbB3 inhibitor is an anti-ErbB3 antibody.

84. The pharmaceutical compositions of claim 83, wherein the anti-ErbB3 antibody comprises the V_H and V_L sequences set forth in SEQ ID NOs: 1 and 2, respectively.

85. The pharmaceutical compositions of any one of claims 79-81, wherein the ErbB3 inhibitor is a bispecific anti-ErbB3, anti-ErbB2 antibody.

86. The pharmaceutical compositions of 85, wherein the bispecific anti-ErbB3, anti-ErbB2 antibody comprises the amino acid sequence set forth in SEQ ID NO:44.

87. The pharmaceutical compositions of claim 85, wherein the bispecific anti-ErbB3, anti-ErbB2 antibody exhibits an insignificant effect upon HER2 mediated signaling.

88. The pharmaceutical compositions of any one of claims 79-81, wherein the ErbB3 inhibitor inhibits PI3K/AKT signaling.

89. The pharmaceutical compositions of any one of claims 79-81, wherein the ErbB pathway inhibitor included in the composition is an anti-EGFR antibody.

90. The pharmaceutical compositions of claim 89, wherein the anti-EGFR antibody comprises cetuximab.
91. The pharmaceutical compositions of any one of claims 79-81, wherein the ErbB pathway inhibitor included in the composition is a small molecule inhibitor of EGFR signaling.
92. The pharmaceutical compositions of claim 91, wherein the small molecule inhibitor of EGFR signaling is gefitinib.
93. The pharmaceutical compositions of any one of claims 79-81, wherein the ErbB pathway inhibitor included in the composition is an anti-HER2 antibody.
94. The pharmaceutical compositions of claim 93, wherein the anti-HER2 antibody comprises trastuzumab.
95. The pharmaceutical compositions of any one of claims 79-81, wherein the tumor is a lung cancer.
96. The pharmaceutical compositions of claim 95, wherein the lung cancer is a non-small cell lung cancer selected from an adenocarcinoma, a squamous cell carcinoma and a large cell carcinoma.
97. The pharmaceutical compositions of claim 95, wherein the tumor comprises tumor cells comprising one or more of a T790M EGFR mutation, a G12S, G12C, or G12V KRAS mutation, and a Q61R KRAS mutation.
98. The pharmaceutical compositions of claim 95, wherein the tumor is a non-small cell lung cancer selected from an adenocarcinoma, a squamous cell carcinoma and a large cell carcinoma and the tumor further comprises tumor cells comprising one or more of a T790M EGFR mutation, a G12S, G12C, or G12V KRAS mutation, and a Q61R KRAS mutation.




Fig. 1





Fig. 1
(Continued)

Figure 2A

H322M NSCLC Cell Line






Figure 2C

A549 NSCLC Cell Line




Figure 2D

H358 NSCLC Cell Line




Figure 2E

SW-900 NSCLC Cell Line




Figure 3A

H3222M NSCLC Cell Line




Figure 3B

EKVX NSCLC Cell Line




Figure 3C

A549 NSCLC Cell Line




Figure 3D

H358 NSCLC Cell Line




Figure 3E

NCI-H441 NSCLC Cell Line




Figure 3F

NCI-H2347 NSCLC Cell Line




Figure 3G

NCI-H2170 NSCLC Cell Line





Figure 3H

NCI-H661 NSCLC Cell Line






Fig. 4

A2780 (sensitive)





Fig. 5A

A2780cis (resistant)

time(h)



Cisplatin (μM)

Fig. 5B

A2780cis (resistant)

time(h)







R

1

4

24

72



MM-121 (μM)



0.01

0.1

1

Fig. 5C




Figure 6A




Figure 6B




Figure 6C




Figure 7A




Figure 7B




Figure 8A




Figure 8B




Figure 9A




Figure 9B




Figure 9C




Figure 10A




Figure 10B




Figure 11A





Figure 11B

**Figure 12A**




Figure 12B




Figure 13A




Figure 13B




Figure 13C




Figure 14A




Figure 14B




Figure 14C




Figure 14D




Figure 14E




Figure 14F




Figure 14G




Figure 14H




Figure 14I





Figure 15A

**Figure 15B**




Figure 15C




Figure 15D




Figure 16




Figure 17A




Figure 17B




Figure 17C